CA2436846C - Thioether substituted imidazoquinolines - Google Patents

Thioether substituted imidazoquinolines Download PDF

Info

Publication number
CA2436846C
CA2436846C CA2436846A CA2436846A CA2436846C CA 2436846 C CA2436846 C CA 2436846C CA 2436846 A CA2436846 A CA 2436846A CA 2436846 A CA2436846 A CA 2436846A CA 2436846 C CA2436846 C CA 2436846C
Authority
CA
Canada
Prior art keywords
imidazo
butyl
quinolin
amine
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2436846A
Other languages
French (fr)
Other versions
CA2436846A1 (en
Inventor
Joseph F. Dellaria
Bryon A. Merrill
Matthew R. Radmer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
3M Innovative Properties Co
Original Assignee
3M Innovative Properties Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 3M Innovative Properties Co filed Critical 3M Innovative Properties Co
Publication of CA2436846A1 publication Critical patent/CA2436846A1/en
Application granted granted Critical
Publication of CA2436846C publication Critical patent/CA2436846C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4738Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/04Antipruritics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/14Drugs for dermatological disorders for baldness or alopecia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • A61P31/06Antibacterial agents for tuberculosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • A61P31/08Antibacterial agents for leprosy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10Antimycotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/16Antivirals for RNA viruses for influenza or rhinoviruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • A61P31/22Antivirals for DNA viruses for herpes viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/02Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/02Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/08Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis for Pneumocystis carinii
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

Imidazoquinoline and tetrahydroimidazoquinoline compounds that contain thioether functionality at the 1-position are useful as immune response modifiers. The compounds and compositions of the invention can induce the biosynthesis of various cytokines and are useful in the treatment of a variety of conditions including viral diseases and neoplastic diseases.

Description

Thioether Substituted Imidazoquinolines Field of the Invention This invention relates to imidazoquinoline compounds that have thioether functionality at the 1-position, and to pharmaceutical compositions containing such compounds. A further aspect of this invention relates to the use of these compounds as immunomodulators, for inducing cytokine biosynthesis in animals, and in the treatment of diseases, including viral and neoplastic diseases.

Background of the Invention The first reliable report on the 1H-inidazo[4,5-c]quinoline ring system, Backman et at., J. Org. Chem. 15, 1278-1284 (1950) describes the synthesis of 1-(6-methoxy-8-quinolinyl)-2-methyl-lH-imidazo[4,5-c]quinoline for possible use as an antimalarial agent. Subsequently, syntheses of various substituted 1H-imidazo[4,5-c]
quinolines were reported. For example, Jain et al., J. Med. Chem. 11, pp. 87-92 (1968), synthesized the compound 1-[2-(4-piperidyl)ethyl]-1H-imidazo[4,5-c]quinoline as a possible anticonvulsant and cardiovascular agent. Also, Baranov et al., Chem. Abs. 85, (1976), have reported several 2-oxoimidazo[4,5-c]quinolines, and Berenyi et al., J.
Heterocyclic Chem. 18, 1537-1540 (1981), have reported certain 2-oxoimidazo[4,5-c]quinolines.
Certain 1H-imidazo[4,5-c]quinolin-4-amines and 1- and 2-substituted derivatives thereof were later found to be useful as antiviral agents, bronchodilators and immunomodulators. These are described in, inter alia, U.S. Patent Nos.
4,689,338;
4,698,348; 4,929,624; 5,037,986; 5,268,376; 5,346,905; and 5,389,640.
There continues to be interest in the imidazoquinoline ring system.
Certain 1H-imidazo[4,5-c] naphthyridine-4-amines, 1H-imidazo [4,5-c] pyridin-4-amines, and 1H-imidazo[4,5-c] quinolin-4-amines having an ether containing substituent at the 1 position are known. These are described in U.S. Patent Nos.
5,268,376;
5,389,640; 5,494,916; and WO 99/29693.
Despite these attempts to identify compounds that are useful as immune response modifiers, there is a continuing need for compounds that have the ability to modulate the immune response, by induction of cytokine biosynthesis or other mechanisms.
Summary of the Invention We have found a new class of compounds that are useful in inducing cytokine biosynthesis in animals. Accordingly, this invention provides imidazoquinoline-4-amine and tetrahydroimidazoquinoline-4-amine compounds that have a thioether containing substituent at the 1-position. The compounds are defined by Formulas (I) and (II), which are defined in more detail infra. These compounds share the general structural formula:

N
~-R2 N X- Z- Rl Rn P
wherein X, Z, R1, R2, and R are as defined herein for each class of compounds having formulas (I) and (II).
The compounds of formulas (I) and (II) are useful as immune response modifiers due to their ability to induce cytokine biosynthesis and otherwise modulate the immune response when administered to animals. This makes the compounds useful in the treatment of a variety of conditions such as viral diseases and tumors that are responsive to such changes in the immune response.
The invention further provides pharmaceutical compositions containing the immune response modifying compounds, and methods of inducing cytokine biosynthesis in an animal, treating a viral infection in an animal, and/or treating a neoplastic disease in an animal by administering a compound of Formula (I) or (II) to the animal.
In addition, the invention provides methods of synthesizing the compounds of the invention.

As mentioned earlier, we have found certain compounds that induce cytoline biosynthesis and modify the immune response in animals. Such compounds are represented by Formulas (T) and (II) as shown below.
Imidazoquinoline compounds of the invention, which have thioether functionality at the 1-position are represented by Formula (I):

N N
`}-R2 N

X- Z-- RI
(I) wherein: X is -CHR3-, -CHR3-alkyl-, or -CHR3-alkenyl-;
Z is -S-, -SO-, or -SO2-;
R, is: -alkyl;
-aryl;
-heteroaryl;
-heterocyclyl;
-alkenyl;
-R4-aryl;
-R4-heteroaryl; or -R4-heterocyclyl;
R2 is: -hydrogen;
-alkyl;
-alkenyl;
-aryl;
-heteroaryl;
-heterocyclyl;
-alkyl-Y-alkyl;
- alkyl-Y- alkenyl;
-alkyl-Y-aryl; or - alkyl or alkenyl substituted by one or more substituents being:
-OH;
-halogen;
-N(R3)2;
-CO-N(R3)2;
-CO-C1_10 alkyl;
-CO-0-C1-1o alkyl;
-N3;
-aryl;
-heteroaryl;
-heterocyclyl;
-CO-aryl; or -CO-heteroaryl;
each R3 is independently H or C1-10 alkyl;
each R4 is independently alkyl or alkenyl;
each Y is independently -0- or -S(O)0_2_;
n is 0 to 4; and each R present is independently C1_10 alkyl, C1_10 alkoxy, hydroxy, halogen or trifluoromethyl;
or a pharmaceutically acceptable salt thereof.

The invention is also directed to a compound being:
2-butyl-1-[4-(phenylthio)butyl]-1H-imidazo[4,5-c]quinolin-4-amine;
2-butyl-1-[2-(phenylthio)ethyl]-6,7,8,9-tetrahydro-lH-imidazo[4,5-c]quinolin-4-amine;
2-butyl-1-[4-(phenylsulfonyl)butyl] -1 H-imidazo [4, 5 -c] quinolin-4-amine;
2-butyl-1-[4-(methylthio)butyl]-1H-imidazo[4,5-c]quinolin-4-amine;
2-butyl-l-[4-(methylsulfonyl)butyl]-1H-imidazo[4,5-c]quinolin-4-amine;
1-[2-(phenylthio)ethyl]-1H-imidazo[4,5-c]quinolin-4-amine;
1 - [4-(phenylsulfonyl)butyl] - I H-imidazo [4, 5 -c] quinolin-4-amine;
1 - [4-(methylsulfonyl)butyl] -1 H-imidazo [4, 5 -c] quino lin-4-amine;
1 -[4-(phenylthio)butyl]-I H-imidazo [4,5-c]quinolin-4-amine;
1 -[4-(methylthio)butyl]-1 H-imidazo [4, 5 -c]quinolin-4-amine;
2-butyl-1-[5-(methylsulfonyl)pentyl]-1H-imidazo[4,5-c]quinolin-4-amine;
2-methyl-1 -[5-(methylsulfonyl)pentyl]-1H-imidazo[4,5-c]quinolin-4-amine;
2-ethyl- l - [5-(methylsulfonyl)pentyl]-1H-imidazo [4,5-c]quinolin-4-amine;
1-[5-(methylsulfonyl)pentyl]-1H-imidazo[4,5-c]quinolin-4-amine;
2-hexyl-l-[5-(methylsulfonyl)pentyl]-1H-imidazo[4,5-c]quinolin-4-amine;
2-(2-methoxyethyl)-1-[5-(methylsulfonyl)pentyl]-1H-imidazo[4,5-c]quinolin-4-amine;
2-butyl-1-[5-(methylthio)pentyl]-1H-imidazo[4,5-c]quinolin-4-amine;
2-butyl-1-[5-(methylsulfnyl)pentyl]-1H-imidazo[4,5-c]quinolin-4-amine;
2-butyl-1-[3-(methylsulfonyl)propyl]-1 H-imidazo[4,5-c]quinolin-4-amine; or 2-butyl-l-[3-(phenylsulfonyl)propyl]-1H-imidazo[4,5-c]quinolin-4-amine;
or a pharmaceutically acceptable salt thereof.

The invention also includes tetrahydroiinidazoquinoline compounds that bear a thioether containing substituent at the 1-position. Such tetrahydroimidazoquinoline compounds are represented by Formula (II):
N N
R

N
I

(II) wherein: X is -CHR3-, -CHR3-alkyl-, or -CHR3-alkenyl-;
Z is -S-, -SO-, or -SO2-;
R1 is: -alkyl;
-aryl;
-heteroaryl;
-heterocyclyl;
-alkenyl;
-R4-aryl;
-R4- heteroaryl; or -R4-heterocyclyl;
R2 is: -hydrogen;
-alkyl;
-alkenyl;
-aryl;
-heteroaryl;
-heterocyclyl;
-alkyl-Y-alkyl;
-alkyl-Y-alkenyl;
-alkyl-Y-aryl; or - alkyl or alkenyl substituted by one or more substituents being:
-OH;
-halogen;
-N(R3)2;
-CO-N(R3)2;
-CO-Cl_1o alkyl;
-CO-O-Ci_io alkyl;
-N3;
-aryl;
-heteroaryl;
-heterocyclyl;
-CO-aryl; or -CO-heteroaryl;
each R3 is independently H or Ci_io alkyl;
each R4 is independently alkyl or alkenyl;
each Y is independently -0- or -S(O)0_2_;
n is 0 to 4; and each R present is independently CI-10 alkyl, Ci_1o alkoxy, hydroxy, halogen or trifluoromethyl;
or a pharmaceutically acceptable salt thereof.

The invention is further directed to a pharmaceutical composition comprising a compound or a pharmaceutically acceptable salt thereof as defined above, and a pharmaceutically acceptable carrier.

The invention is yet directed to the use of a compound as defined above for:
- inducing cytokine biosynthesis in an animal, preferably the cytokine being IFN-a.;
- for treating a viral disease in an animal; or - for treating neoplastic disease in an animal.
6a The invention is yet directed to the use of a compound as defined above for the manufacture of a medicament for:
- inducing cytokine biosynthesis in an animal, preferably the cytokine being IFN-a;
- treating a viral disease in an animal; or - treating a neoplastic disease in an animal.
DETAILED DESCRIPTION OF THE INVENTION
Preparation of the Compounds Compounds of the invention can be prepared according to Reaction Scheme I
where R, R1, R2, X and n are as defined above.
In step (1) of Reaction Scheme I a 4-chloro-3-nitroquinoline of Formula X is reacted with an amine of formula HO-X-NH2 to provide a 3-nitroquinolin-4-amine of Formula XI. The reaction can be carried out by adding the amine to a solution of a compound of Formula X in a suitable solvent such as chloroform or dichloromethane in the presence of triethylamine and optionally heating. Many quinolines of Formula X are known compounds (see for example, U.S. Patent 4,689,338 and references cited therein).

6b Many amines of formula HO-X-NH2 are commercially available; others can be readily prepared using known synthetic routes.
In step (2) of Reaction Scheme I a 3-nitroquinolin-4-amine of Formula XI is chlorinated to provide a 3-nitroquinolin-4-amine of Formula XII. Conventional chlorinating agents can be used. Preferably the reaction is carried out by combining a compound of Formula XI with thionyl chloride in a suitable solvent such as dichloromethane and heating. Alternatively the reaction may be run neat.
In step (3) of Reaction Scheme I a 3-nitroquinolin-4-amine of Formula XII is reduced to provide a quinoline-3,4-diamine of Formula XIII. Preferably, the reduction is carried out using a conventional heterogeneous hydrogenation catalyst such as platinum on carbon. The reaction can conveniently be carried out on a Parr apparatus in a suitable solvent such as toluene.
In step (4) of Reaction Scheme I a quinoline-3,4-diamine of Formula XIII is reacted with a carboxylic acid or an equivalent thereof to provide a 1H-imidazo[4,5-c]quinoline of Formula XIV. Suitable equivalents to a carboxylic acid include orthoesters, and 1, 1 -dialkoxyalkyl alkanoates. The carboxylic acid or equivalent is selected such that it will provide the desired R2 substituent in a compound of Formula XIV. For example, triethyl orthoformate will provide a compound where R2 is hydrogen and trimethyl orthovalerate will provide a compound where R2 is butyl. The reaction can be run in the absence of solvent or in an inert solvent such as toluene. The reaction is run with sufficient heating to drive off any alcohol or water formed as a byproduct of the reaction.
Optionally a catalyst such as pyridine hydrochloride can be included.
Alternatively, step (4) can be carried out by (i) reacting the diamine of Formula XIII with an acyl halide of Formula R2C(O)Cl or R2C(O)Br and then (ii) cyclizing. In part (i) the acyl halide is added to a solution of the diamine in a suitable solvent such as pyridine. The reaction can be carried out at ambient temperature. In part (ii) the product of part (i) is heated in pyridine in the presence of pyridine hydrochloride.
In step (5) of Reaction Scheme I a 1H-imidazo[4,5-c]quinoline of Formula XIV
is oxidized to provide a IH-imidazo[4,5-c]quinoline-5N-oxide of Formula XV using a conventional oxidizing agent capable of forming N-oxides. Preferably a solution of a compound of Formula XIV in a suitable solvent such as chloroform or dichloromethane is treated with 3-chloroperoxybenzoic acid at ambient temperature.
In step (6) of Reaction Scheme I a lH-imidazo[4,5-c]quinoline-5N-oxide of Formula XV is aminated to provide a 1H-imidazo[4,5-c]quinolin-4-amine of Formula XVI. Step (6) involves (i) reacting a compound of Formula XV with an acylating agent and then (ii) reacting the product with an aminating agent. Part (i) of step (6) involves reacting an N-oxide of Formula XV with an acylating agent. Suitable acylating agents include alkyl- or arylsulfonyl chlorides (e.g., benezenesulfonyl chloride, methanesulfonyl chloride, p-toluenesulfonyl chloride). Arylsulfonyl chlorides are preferred.
Para-toluenesulfonyl chloride is most preferred. Part (ii) of step (6) involves reacting the product of part (i) with an excess of an aminating agent. Suitable aminating agents include ammonia (e.g., in the form of ammonium hydroxide) and ammonium salts (e.g., ammonium carbonate, ammonium bicarbonate, ammonium phosphate). Ammonium hydroxide is preferred. The reaction is preferably carried out by dissolving the N-oxide of Formula XV in an inert solvent such as dichloromethane or chloroform, adding the aminating agent to the solution, and then slowly adding the acylating agent.
In step (7) of Reaction Scheme I a 1H-imidazo[4,5-c]quinolin-4-amine of Formula XVI is reacted with a compound of Formula Rl-SNa to provide a 1H-imidazo[4,5-c]quinolin-4-amine of Formula XVII which is a subgenus of Formula I. The reaction can be carried out by combining a compound of Formula XVI with a compound of formula Rl SNa in a suitable solvent such as N,N-dimethylformamide or dimethyl sulfoxide and heating (60-80 C). The product or a pharmaceutically acceptable salt thereof can be isolated using conventional methods.

In step (8) of Reaction Scheme I a 1H-imidazo[4,5-c]quinolin-4-amine of Formula XVII is oxidized using a conventional oxidizing agent to provide a 1H-imidazo[4,5-c]quinolin-4-amine of Formula XVIII which is a subgenus of Formula I.
Preferably a solution of a compound of Formula XVII in a suitable solvent such as chloroform or dichloromethane is treated with 3-chloroperoxybenzoic acid at ambient temperature. The degree of oxidation is controlled by adjusting the amount of 3-chloroperoxybenzoic acid used in the reaction; i.e., using approximately one equivalent will provide the sulfoxide whereas using two equivalents will provide the sulfone. The product or a pharmaceutically acceptable salt thereof can be isolated using conventional methods.
Reaction Scheme I

11+ 11+ O+
N 11 j N~O (~) &N- N.O- (2) N N,C3-- 1 CI NH NH

/
n X Rn / x X OH

(3) N} R2 (5) N N} R (4) N NH2 N NH
R,, / X Rn X Rn X
CI CI Cl XV XIV XIII
(6) NH2 NH5III\-R2 NH2 N N R2 (7) N (8) N N

I \> 30 1 X R5J>-R2 X
CI S S(O)S-z XVI XVII R, XVIII
R~
Compounds of the invention can be prepared according to Reaction Scheme II
where R, R1, R2, X and n are as defined above.
In step (1) of Reaction Scheme II a 3-nitroquinolin-4-amine of Formula XII is reacted with a compound of the Formula Rl-SNa using the method of step (7) of Reaction Scheme Ito provide a 3-nitroquinolin-4-amine of Formula XIX.
In step (2) of Reaction Scheme II a 3-nitroquinolin-4-amine of Formula XIX is reduced using the method of step (3) of Reaction Scheme I to provide a quinoline-3,4-diamine of Formula XX.
In step (3) of Reaction Scheme II a quinoline-3,4-diamine of Formula XX is cyclized using the method of step (4) of Reaction Scheme Ito provide a 1H-imidazo[4,5-c]quinoline of Formula XXI.

In step (4) of Reaction Scheme II a lH-imidazo[4,5-c]quinoline of Formula XXI
is oxidized to provide a 1H-imidazo[4,5-c]quinolin-5N-oxide of Formula XXII using a conventional oxidizing agent. Preferably a solution of a compound of Formula XXI in a suitable solvent such as chloroform or dichloromethane is treated with at least three equivalents of 3-chloroperoxybenzoic acid at ambient temperature.
In step (5) of Reaction Scheme II a 1H-imidazo[4,5-c]quinolin-5N-oxide of Formula XXII is aminated using the method of step (6) of Reaction Scheme Ito provide a 1H-imidazo[4,5-c]quinolin-4-amine of Formula XVIII which is a subgenus of Formula I.
The product or a pharmaceutically acceptable salt thereof can be isolated using conventional methods.

Reaction Scheme II
0+ 0+
N,- N, - NHN 0(1) N 0(2). N 2 NH NH NH
Rn / X Rn / X Rn / X
XII CI XIX ~ XX S
Ri R1 (3) NHz N NR2 (5) N / N -R2 (4) N N~Rz N N N
Rn - i Rn / X Rn / X
S

Ri Ri Compounds of the invention can be prepared according to Reaction Scheme III
where R, R1, R2, X and n are as defined above.
In step (1) of Reaction Scheme III a 3-nitro-4-amino-quinolin-1-yl alcohol of Formula XI is protected with a tent-butyldimethylsilyl group using conventional methods.
Preferably a compound of Formula XI is combined with tert-butyldimethylsilyl chloride in a suitable solvent such as chloroform in the presence of triethylamine and a catalytic amount of 4-dimethylaminopyridine.
In step (2) of Reaction Scheme III a protected 3-nitro-4-amino-quinolin-l-yl alcohol of Formula XXIII is reduced using the method of step (3) of Reaction Scheme Ito provide a protected 3, 4-diamino-quinolin-l-yl alcohol of Formula XXIV.
In step (3) of Reaction Scheme III a protected 3,4-diamino-quinolin-l-yl alcohol of Formula XXIV is cyclized using the method of step (4) of Reaction Scheme Ito provide a 1H-imidazo[4,5-c]quinoline of Formula XXV.
In step (4) of Reaction Scheme III a 1H-imidazo[4,5-c]quinoline of Formula XXV
is oxidized using the method of step (5) of Reaction Scheme Ito provide a IH-imidazo[4,5-c]quinolin-5N-oxide of Formula XXVI.
In step (5) of Reaction Scheme III a 1H-imidazo[4,5-c]quinolin-5N-oxide of Formula XXVI is aminated using the method of step (6) of Reaction Scheme Ito provide a IH-imidazo[4,5-c]quinolin-4-amine of Formula XXVII.
In step (6) of Reaction Scheme III the protecting group is removed from a 1H-imidazo[4,5-c]quinolin-4-amine of Formula XXVII to provide a IH-imidazo[4,5-c]quinolin-4-amine of Formula XXVIII. Preferably a solution of a compound of Formula XXVII in a suitable solvent such as tetrahydrofuran is treated with tetrabutylammonium fluoride. Some compounds of Formula XXVIII are known, see for example, Gerster, U.S.
Patent No. 4,689,338 and Gerster et al., U.S. Patent 5,605,899.
In step (7) of Reaction Scheme III a 1H-imidazo[4,5-c]quinolin-4-amine of Formula XXVIII is chlorinated using conventional methods to provide a 1H-imidazo[4,5-c]quinolin-4-amine of Formula XVI. A compound of Formula XXVIII can be heated neat with thionyl chloride. Alternatively, phosphorous oxychloride can be added in a controlled fashion to a solution of a compound of Formula XXVIII in a suitable solvent such as N,N-dimethylformamide in the presence of triethylamine.

Steps (8) and (9) of Reaction Scheme III can be carried out in the same manner as steps (7) and (8) respectively of Reaction Scheme I.

Reaction Scheme III
O+ O
N, 11+
N O (1) _ N N, 0-(2) N NH
/ I
R" / NHz / NH Rn I NH R /
X
OH / / X
O
XI Mil -Si- XXIV I
-Si-A-NHz (3) N O\+ N
I 11 N~ Rz N N R2 (5) N j N)- Rz E (4) N
N
Rn X Rn / X Rn / X
O O i O
XXVII -Si- XXVI -Si- XXV -Si-/~-(6) N % N} RZ (7) N (g) N I NX R5J\>-R2 X Rn X
OH CI S
XXVI I I XVI XVI I I
Ri (9) NHz N
N % \}R2 Rn X
XVIII

Compounds of the invention can be prepared according to Reaction Scheme IV
where R, R1, R2, X and n are as defined above and BOC is tert-butoxycarbonyl.
In step (1) of Reaction Scheme IV the hydroxy group of a 6,7,8,9-tetrahydro-lH-imidazo[4,5-c]quinolin-l-yl alcohol of Formula XXIX is protected with a tert-butyldimethylsilyl group using the method of step (1) of Reaction Scheme III.
Compounds of Formula XXIX are known or can be prepared using known synthetic methods, see for example, Nikolaides, et al., U.S. Patent No.5,352,784 and Lindstrom, U.S. Patent No. 5,693,811 and references cited therein.
In step (2) of Reaction Scheme IV the amino group of a 1H-imidazo[4,5-c]quinolin-4-amine of Formula XXX is protected using conventional methods to provide a protected IH-imidazo[4,5-c]quinoline of Formula XXXI. Preferably a compound of Formula XXX is treated with di-test-butyl dicarbonate in a suitable solvent such as tetrahydrofuran in the presence of triethylamine and 4-dimethylaminopyridine.
The reaction can be run at an elevated temperature (60 C).
In step (3) of Reaction Scheme IV the tert-butyldimethylsilyl protecting group of a compound of Formula XXXI is removed using the method of step (6) of Reaction Scheme III to provide a 1H-imidazo[4,5-c]quinolin-lyl alcohol of Formula XXXII.
In step (4) of Reaction Scheme IV a 1H-imidazo[4,5-c]quinolin-lyl alcohol of Formula XXXII is converted to a methanesulfonate of Formula XXXIII. Preferably a solution of a compound of Formula XXXII in a suitable solvent such as dichloromethane is treated with methanesulfonyl chloride in the presence of triethylamine. The reaction can be run at a reduced temperature (-10 C).
In step (5) of Reaction Scheme IV a methanesulfonate of Formula XXXIII is reacted with a thiol of formula R1SH to provide a thioether of Formula XXXIV.
Preferably a solution of a compound of Formula XXXIII in a suitable solvent such as N, N-dimethylformamide is treated with the thiol in the presence of triethylamine. The reaction can be run at an elevated temperature (80 C).
In step (6) of Reaction Scheme IV the tert-butoxycarbonyl protecting groups are removed by hydrolysis under acidic conditions to provide a 1H-imidazo[4,5-c]quinolin-4-amine of Formula XXXV which is a subgenus of Formula II. Preferably a solution of a compound of Formula XXXIV in a suitable solvent such as dichloromethane is treated at ambient temperature with a solution of hydrochloric acid in dioxane. The product or a pharmaceutically acceptable salt thereof can be isolated using conventional methods.
In step (7) of Reaction Scheme IV a thioether of Formula XXXV is oxidized using the method of step (8) of Reaction Scheme Ito provide a sulfone or sulfoxide of Formula XXXVI which is a subgenus of Formula II. The product or a pharmaceutically acceptable salt thereof can be isolated using conventional methods.

Reaction Scheme IV

NH2 N(BOC)2 N N R2 N N - R () N N> R

Rn X Rn X Rn X
OH O
XXIX XXX -Si- XXXI -Si-(3) NBOC)2 N(BOC)2 N(BOC)2 NJ N
6 N>- R2 N R2 (5) N N R2 N /
N N
Rn X Rn X Rn X
S O OH
XXXIV IR XXXIII O-S-O XXXII

(6) N N>-R2 (7) N N\ -R
j 2 , N
Rn S Rn XXXV R XXXVI T(O)1-2 Compounds of the invention can be prepared according to Reaction Scheme V
where R, R1, R2, X and n are as defined above.

In step (1) of Reaction Scheme V a 6,7,8,9-tetrahydro-lH-imidazo[4,5-c]quinolin-1-yl alcohol of Formula XXIX is chlorinated using the method of step (7) of Reaction Scheme III to provide a compound of Formula XXXVII.
In step (2) of Reaction Scheme V a compound of Formula XXXVII is reacted with a compound of formula Rl-SNa using the method of step (7) of Reaction Scheme Ito provide a thioether of Formula XXXV which is a subgenus of Formula II. The product or a pharmaceutically acceptable salt thereof can be isolated using conventional methods.
In step (3) of Reaction Scheme V a thioether of Formula XXXV is oxidized using the method of step (8) of Reaction Scheme Ito provide a sulfone or sulfoxide of Formula XXXVI which is a subgenus of Formula II. The product or a pharmaceutically acceptable salt thereof can be isolated using conventional methods.

Reaction Scheme V

N N (1) (2) -R2 ~ -R2 N R2 N
R X Rn X Rõ X
OH CI S
XXIX XXXVII XXXV
Ri (3) N N
}R2 N
R" X
S(0)a_2 XXXVI

As used herein, the terms "alkyl", "alkenyl" and the prefix "alk-" are inclusive of both straight chain and branched chain groups and of cyclic groups, i.e.
cycloalkyl and cycloalkenyl. Unless otherwise specified, these groups contain from 1 to 20 carbon atoms, with alkenyl groups containing from 2 to 20 carbon atoms. Preferred groups have a total of up to 10 carbon atoms. Cyclic groups can be monocyclic or polycyclic and preferably have from 3 to 10 ring carbon atoms. Exemplary cyclic groups include cyclopropyl, cyclopropylmethyl, cyclopentyl, cyclohexyl and adamantyl.
In addition, the alkyl and alkenyl portions of -X- groups can be unsubstituted or substituted by one or more substituents, which substituents are selected from the groups consisting of alkyl, alkenyl, aryl, heteroaryl, heterocyclyl, arylalkyl, heteroarylalkyl, and heterocyclylalkyl.
The term "haloalkyl" is inclusive of groups that are substituted by one or more halogen atoms, including perfluorinated groups. This is also true of groups that include the prefix "halo". Examples of suitable haloalkyl groups are chloromethyl, trifluoromethyl, and the like.
The term "aryl" as used herein includes carbocyclic aromatic rings or ring systems.
Examples of aryl groups include phenyl, naphthyl, biphenyl, fluorenyl and indenyl. The term "heteroaryl" includes aromatic rings or ring systems that contain at least one ring hetero atom (e.g., 0, S, N). Suitable heteroaryl groups include furyl, thienyl, pyridyl, quinolinyl, isoquinolinyl, indolyl, isoindolyl, triazolyl, pyrrolyl, tetrazolyl, imidazolyl, pyrazolyl, oxazolyl, thiazolyl, benzofuranyl, benzothiophenyl, carbazolyl, benzoxazolyl, pyrimidinyl, benzimidazolyl, quinoxalinyl, benzothiazolyl, naphthyridinyl, isoxazolyl, isothiazolyl, purinyl, quinazolinyl, and so on.
"Heterocyclyl" includes non-aromatic rings or ring systems that contain at least one ring hetero atom (e.g., 0, S, N) and includes all of the fully saturated and partially unsaturated derivatives of the above mentioned heteroaryl groups. Exemplary heterocyclic groups include pyrrolidinyl, tetrahydrofuranyl, morpholinyl, thiomorpholinyl, piperidinyl, piperazinyl, thiazolidinyl, imidazolidinyl, isothiazolidinyl, and the like.
The aryl, heteroaryl, and heterocyclyl groups can be unsubstituted or substituted by one or more substituents independently selected from the group consisting of alkyl, alkoxy, alkylthio, haloalkyl, haloalkoxy, haloalkylthio, halogen, nitro, hydroxy, mercapto, cyano, carboxy, formyl, aryl, aryloxy, arylthio, arylalkoxy, arylalkylthio, heteroaryl, heteroaryloxy, heteroarylthio, heteroarylalkoxy, heteroarylalkylthio, amino, alkylamino, dialkylamino, heterocyclyl, heterocycloalkyl, alkylcarbonyl, alkenylcarbonyl, alkoxycarbonyl, haloalkylcarbonyl, haloalkoxycarbonyl, alkylthiocarbonyl, arylcarbonyl, heteroarylcarbonyl, aryloxycarbonyl, heteroaryloxycarbonyl, arylthiocarbonyl, heteroarylthiocarbonyl, alkanoyloxy, alkanoylthio, alkanoylamino, arylcarbonyloxy, arylcarbonylthio, alkylaminosulfonyl, alkylsulfonyl, arylsulfonyl, heteroarylsulfonyl, aryldiazinyl, alkylsulfonylamino, arylsulfonylamino, arylalkylsulfonylamino, alkylcarbonylamino, alkenylcarbonylamino, arylcarbonylamino, arylalkylcarbonylamino, heteroarylcarbonylamino, heteroarylalkycarbonylamino, alkylsulfonylamino, alkenylsulfonylamino, arylsulfonylamino, arylalkylsulfonylamino, heteroaiylsulfonylamino, heteroarylalkylsulfonylamino, alkylaminocarbonylamino, alkenylaminocarbonylamino, arylaminocarbonylamino, arylalkylaminocarbonylamino, heteroarylaminocarbonylamino, heteroarylalkylcarbonylamino, and, in the case of heterocyclyl, oxo. If any other groups are identified as being "substituted"
or "optionally substituted", then those groups can also be substituted by one or more of the above enumerated substituents.
Certain substituents are generally preferred. For example, preferred X groups include ethylene and n-butylene and preferred Rl groups are alkyl and aryl, with phenyl or substituted phenyl a preferred aryl group. Preferably no R substituents are present (i.e., n is 0). Preferred R2 groups include hydrogen, alkyl groups having 1 to 4 carbon atoms (i.e., methyl, ethyl, propyl, isopropyl, n-butyl, sec-butyl, isobutyl, and cyclopropylmethyl), methoxyethyl, and ethoxymethyl. One or more of these preferred substituents, if present, can be present in the compounds of the invention in any combination.

The invention is inclusive of the compounds described herein in any of their pharmaceutically acceptable forms, including isomers (e.g., diastereomers and enantiomers), salts, solvates, polymorphs, and the like. In particular, if a compound is optically active, the invention specifically includes each of the compound's enantiomers as well as racemic mixtures of the enantiomers.

Pharmaceutical Compositions and Biological Activity Pharmaceutical compositions of the invention contain a therapeutically effective amount of a compound of the invention as described above in combination with a pharmaceutically acceptable carrier.
The term "a therapeutically effective amount" means an amount of the compound sufficient to induce a therapeutic effect, such as cytokine induction, antitumor activity, and/or antiviral activity. Although the exact amount of active compound used in a pharmaceutical composition of the invention will vary according to factors known to those of skill in the art, such as the physical and chemical nature of the compound, the nature of the carrier, and the intended dosing regimen, it is anticipated that the compositions of the invention will contain sufficient active ingredient to provide a dose of about 100 ng/kg to about 50 mg/kg, preferably about 10 g/kg to about 5 mg/kg, of the compound to the subject. Any of the conventional dosage forms may be used, such as tablets, lozenges, parenteral formulations, syrups, creams, ointments, aerosol formulations, transdermal patches, transmucosal patches and the like.
The compounds of the invention can be administered as the single therapeutic agent in the treatment regimen, or the compounds of the invention may be administered in combination with one another or with other active agents, including additional immune response modifiers, antivirals, antibiotics, etc.
The compounds of the invention have been shown to induce the production of certain cytokines in experiments performed according to the tests set forth below. These results indicate that the compounds are useful as immune response modifiers that can modulate the immune response in a number of different ways, rendering them useful in the treatment of a variety of disorders.
Cytokines whose production may be induced by the administration of compounds according to the invention generally include interferon-a (IFN-a) and/or tumor necrosis factor-a (TNF-a) as well as certain interleukins (IL). Cytokines whose biosynthesis may be induced by compounds of the invention include IFN-a, TNF-a, IL-1, IL-6, IL-10 and IL-12, and a variety of other cytokines. Among other effects, these and other cytokines can inhibit virus production and tumor cell growth, making the compounds useful in the treatment of viral diseases and tumors. Accordingly, the invention provides a method of inducing cytokine biosynthesis in an animal comprising administering an effective amount of a compound or composition of the invention to the animal.
Certain compounds of the invention have been found to preferentially induce the expression of IFN-a in a population of hematopoietic cells such as PBMCs (peripheral blood mononuclear cells) containing pDC2 cells (precursor dendritic cell-type 2) without concomitant production of significant levels of inflammatory cytokines.
In addition to the ability to induce the production of cytokines, the compounds of the invention affect other aspects of the innate immune response. For example, natural killer cell activity may be stimulated, an effect that may be due to cytokine induction. The compounds may also activate macrophages, which in turn stimulates secretion of nitric oxide and the production of additional cytokines. Further, the compounds may cause proliferation and differentiation of B-lymphocytes.
Compounds of the invention also have an effect on the acquired immune response.
For example, although there is not believed to be any direct effect on T cells or direct induction of T cell cytokines, the production of the T helper type 1 (Thl) cytokine IFN-y is induced indirectly and the production of the T helper type 2 (Th2) cytokines IL-4, IL-5 and IL-13 are inhibited upon administration of the compounds. This activity means that the compounds are useful in the treatment of diseases where upregulation of the Thl response and/or downregulation of the Th2 response is desired. In view of the ability of compounds of the invention to inhibit the Th2 immune response, the compounds are expected to be useful in the treatment of atopic diseases, e.g., atopic dermatitis, asthma, allergy, allergic rhinitis; systemic lupus erythematosis; as a vaccine adjuvant for cell mediated immunity; and possibly as a treatment for recurrent fungal diseases and chlamydia.
The immune response modifying effects of the compounds make them useful in the treatment of a wide variety of conditions. Because of their ability to induce the production of cytokines such as IFN-a and/or TNF-a, the compounds are particularly useful in the treatment of viral diseases and tumors. This immunomodulating activity suggests that compounds of the invention are useful in treating diseases such as, but not limited to, viral diseases including genital warts; common warts; plantar warts; Hepatitis B; Hepatitis C; Herpes Simplex Virus Type I and Type II; molluscum contagiosum;
variola, particularly variola major; HIV; CMV; VZV; rhinovirus; adenovirus;
influenza;

and para-influenza; intraepithelial neoplasias such as cervical intraepithelial neoplasia;
human papillomavirus (HPV) and associated neoplasias; fungal diseases, e.g.
candida, aspergillus, and cryptococcal meningitis; neoplastic diseases, e.g., basal cell carcinoma, hairy cell leukemia, Kaposi's sarcoma, renal cell carcinoma, squamous cell carcinoma, myelogenous leukemia, multiple myeloma, melanoma, non-Hodgkin's lymphoma, cutaneous T-cell lymphoma, and other cancers; parasitic diseases, e.g.
pneumocystis carnii, cryptosporidiosis, histoplasmosis, toxoplasmosis, trypanosome infection, and leishmaniasis; and bacterial infections, e.g., tuberculosis, and mycobacterium avium.
Additional diseases or conditions that can be treated using the compounds of the invention include actinic keratosis; eczema; eosinophilia; essential thrombocythaemia;
leprosy;
multiple sclerosis; Ommen's syndrome; discoid lupus; Bowen's disease; Bowenoid papulosis; alopecia areata; the inhibition of Keloid formation after surgery and other types of post-surgical scars. In addition, these compounds could enhance or stimulate the healing of wounds, including chronic wounds. The compounds may be useful for treating the opportunistic infections and tumors that occur after suppression of cell mediated immunity in, for example, transplant patients, cancer patients and HIV
patients.
An amount of a compound effective to induce cytokine biosynthesis is an amount sufficient to cause one or more cell types, such as monocytes, macrophages, dendritic cells and B-cells to produce an amount of one or more cytokines such as, for example, IFN-a, TNF-a, IL-1, IL-6, IL-10 and IL-12 that is increased over the background level of such cytokines. The precise amount will vary according to factors known in the art but is expected to be a dose of about 100 ng/kg to about 50 mg/kg, preferably about 10 g/kg to about 5 mg/kg. The invention also provides a method of treating a viral infection in an animal and a method of treating a neoplastic disease in an animal comprising administering an effective amount of a compound or composition of the invention to the animal. An amount effective to treat or inhibit a viral infection is an amount that will cause a reduction in one or more of the manifestations of viral infection, such as viral lesions, viral load, rate of virus production, and mortality as compared to untreated control animals. The precise amount will vary according to factors known in the art but is expected to be a dose of about 100 ng/kg to about 50 mg/kg, preferably about 10 g/kg to about 5 mg/kg. An amount of a compound effective to treat a neoplastic condition is an amount that will cause a reduction in tumor size or in the number of tumor foci. Again, the precise amount will vary according to factors known in the art but is expected to be a dose of about 100 ng/kg to about 50 mg/kg, preferably about 10 gg/kg to about 5 mg/kg.
The invention is further described by the following examples, which are provided for illustration only and are not intended to be limiting in any way.
Example 1 2-butyl- l -[4-(phenylthio)butyl]-1H-imidazo[4,5-c]quinolin-4-amine NHZ
N N
N
S `

Part A

A round bottom flask was charged with a magnetic stir bar, 4-chloro-3-nitroquinoline (109.70 g, 525.87 mmol) and dichloromethane (500 mL). To the solution was added triethylamine (79.82 g, 788.81 mmol) and 4-amino-l-butanol (46.87 g, 525.87 mmol) to give a homogeneous, dark yellow solution. The reaction was judged to be complete after heating at reflux for 30 minutes. The solution was cooled and then partitioned between chloroform and saturated aqueous ammonium chloride. The layers were separated and the aqueous layer was extracted with chloroform (lx). The organic layers were combined and then concentrated under reduced pressure to afford of 4-[(3-nitroquinolin-4-yl)amino]butan- 1 -ol (104.67 g, 400.60 mmol) as a dark yellow solid. This material was used without further purification.
Part B
A round bottom flask was charged with a magnetic stir bar, 4-[(3-nitroquinolin-yl)amino]butan-1-ol (5.0 g, 19.14 mmol), triethylamine (2.91 g, 28.71 mmol), tert-butyldimethylsilyl chloride (3.75 g, 24.9 mmol), 4-dimethylaminopyridine (0.10 g) and chloroform (40 mL) to give a dark yellow solution. The reaction was judged was to complete after stirring at ambient temperature for 2 hours. The solution was partitioned between ethyl acetate and saturated aqueous ammonium chloride. The layers were separated and the organic layer was washed with saturated aqueous sodium bicarbonate, dried over anhydrous sodium sulfate, filtered and then concentrated under reduced pressure to afford N-(4-{[tent-butyl(dimethyl)silyl]oxy}butyl)-3-nitroquinolin-4-amine (6.05 g, 16.11 mmol) as a yellow-green solid. This material was used without further purification. MS (CI) for C19H29N3O3Si m/z 376 (MH), 342, 210.
Part C
A Parr vessel was charged with N-(4-{[tent-butyl(dimethyl)silyl]oxy}butyl)-3-nitroquinolin-4-amine (6.05 g, 16.11 mmol), 5% platinum on carbon (3.0 g), and toluene (32 mL). The vessel was placed on a Parr shaker and pressurized to 50 psi (3.5 Kg/cm2) hydrogen. After shaking for one hour, more catalyst (3.0 g) and toluene (15 mL) were added and the vessel was pressurized to 50 psi (3.5 Kg/cm2) hydrogen and shaking continued. The reaction was judged to be complete after one hour. The catalyst was removed by filtration through fluted paper. The filter cake was washed with toluene (50 mL) and the filtrates were combined. The volatiles were removed under reduced pressure to afford N-(4-f [tert-butyl(dimethyl)silyl]oxy}butyl)quinoline-3,4-diamine (5.57 g, 16.11 ramol) as a dark oil. The material was used without further purification.
Part D
A round bottom flask was charged with a magnetic stir bar, N-(4-{[tert-butyl(dimethyl)silyl]oxy}butyl)quinoline-3,4-diamine (5.57 g, 16.11 mmol), trimethyl orthovalerate (5.23 g, 32.22 mmol) and toluene (47 mL). The reaction was heated to maintain a reflux that brought about a slow distillation to facilitate removal of the methanol byproduct. The reaction was judged to be complete after 15 hours at reflux.
The reaction was cooled and the volatiles were removed under reduced pressure to afford of 2-butyl-l -(4- {[tent-butyl(dimethyl)silyl]oxy}butyl)-1H-imidazo[4,5-c]
quinoline (4.65 g, 11.30 mmol) as a thick, dark brown oil. The material was used without further purification. MS (CI) for C24H37N3OSi m/z 412 (MH), 298.
Part E
A round bottom flask was charged with a magnetic stir bar, 2-butyl- 1 -(4- {
[tert-butyl(dimethyl)silyl]oxy}butyl)-1H-imidazo[4,5-c]quinoline (4.65 g, 11.30 mmol) and chloroform (57 mL). Solid 3-chloroperbenzoic acid (2.78 g, 12.43 mmol) was added portion wise to the solution over 15 minutes and the reaction was stirred at ambient temperature for 1 hour. More 3-chloroperbenzoic acid (0.5g, 2.9 mmol) was added and after 30 minutes the starting material was completely consumed. The solution was partitioned between chloroform and aqueous saturated sodium bicarbonate. The layers were separated. The organic layer was washed with saturated aqueous sodium bicarbonate and brine, dried over anhydrous sodium sulfate, filtered and then concentrated under reduced pressure to afford 2-butyl-l-(4-{[tent-butyl(dimethyl)silyl]oxy}butyl)-imidazo[4,5-c]quinoline-5N-oxide (4.83 g, 11.30 mmol) as a dark oil. The material was used without further purification.
Part F
A round bottom flask was charged with a magnetic stir bar, 2-butyl-1-(4-{[tert-butyl(dimethyl)silyl]oxy}butyl)-1H-imidazo[4,5-c]quinoline-5N-oxide (11.30 mmol) and anhydrous dimethyl formamide (57 mL) under a nitrogen atmosphere. Phosphorus oxychloride (1.91 g, 12.43 mmol) was added to the reaction mixture in a drop wise fashion to give a homogeneous solution after complete addition. The reaction was judged to be complete after stirring for 1.5 hours at ambient temperature and was then partitioned between dichloromethane and saturated aqueous sodium bicarbonate. The layers were separated and the organic portion was washed with aqueous saturated sodium bicarbonate and brine, dried over anhydrous sodium sulfate, filtered and then concentrated under reduced pressure to afford 2-butyl-4-chloro-l-(4-chlorobutyl)-1H-imidazo[4,5-c]quinoline (3.65 g, 10.42 mmol) as a dark brown solid. The material was used without further purification. MS (CI) for C18H21C12N3 m/z 350 (MH+), 314.
Part G

A round bottom flask was charged with a magnetic stir bar, 2-butyl-4-chloro- 1 -(4-chlorobutyl)-1H-imidazo[4,5-c]quinoline (1.18 g, 3.37 mmol), benzenethiol (0.56 g, 5.05 mmol), triethylamine (0.68 g, 6.74 mmol), and dimethyl formamide (15 mL) under a nitrogen atmosphere. The reaction mixture was heated to 80 C to give a homogeneous solution that was maintained at 80 C for 2.5 hours. HPLC analysis indicated no starting material and a 3:1 mixture of 2-butyl-4-chloro-l-[4-(phenylthio)butyl]-1H-imidazo[4,5-c]quinoline and 2-butyl-4-(phenylthio)-I-[4-(phenylthio)butyl]-1H-imidazo[4,5-c]quinoline. The solution was cooled and then partitioned between ethyl acetate and aqueous saturated sodium bicarbonate. The layers were separated and the organic layer was washed with aqueous saturated sodium bicarbonate and brine, dried over anhydrous sodium sulfate, filtered and then concentrated under reduced pressure to afford a 3:1 mixture of the products named above (1.43 g). The material was used without further purification.
Part H
A 3:1 mixture of 2-butyl-4-chloro-l-[4-(phenylthio)butyl]-1H-imidazo[4,5-c]quinoline to 2-butyl-4-(phenylthio)-1-[4-(phenylthio)butyl]-1H-imidazo[4,5-c]quinoline (1.38 g) and a solution of 7% ammonia in methanol (30 mL) were combined in a bomb and heated to 150 C. The reaction was judged to be complete after 5 hours.
The volatiles were removed under reduced pressure and the resulting residue was stirred in water and made basic (pH 10) with solid sodium carbonate. The aqueous mixture was extracted with chloroform (3x). The combined organic layers were washed with saturated aqueous sodium bicarbonate and brine, dried over anhydrous sodium sulfate, filtered and then concentrated under reduced pressure to afford a yellow crystalline solid. The solid (0.8 g) was dissolved in ethyl acetate (50 mL) and brought to reflux. Activated charcoal (0.4 g) was added; the resulting mixture was heated at reflux for 5 minutes and then the charcoal was removed by filtration through fluted paper to provide a colorless solution. The solution was concentrated under reduced pressure to give a solid that was recrystallized from ethyl acetate and hexanes to provide 2-butyl-l-[4-(phenylthio)butyl]-1H-imidazo[4,5-c]quinolin-4-amine (0.51 g, 1.25 mmol) as white needles, m.p. 118-120 C.
Analysis. Calculated for C24H28N4S: %C 71.25; %H, 6.98; %N, 13.85. Found %C
71.12;
%H, 6.81; %N, 13.62 'H-NMR (300 MHz, DMSO) b 8.02 (d, J = 8.3 Hz, IH), 8 7.61 (d, J = 8.3 Hz, 1H), 6 7.41 (t, J = 8.3 Hz, 1H), S 7.16-7.30 (m, 6H), S 6.46 (bs, 2H), S 4.52 (t, J = 7.6 Hz, 2H), S 3.02 (t, J = 7.3 Hz, 2H), 6 2.89 (t, J = 7.8 Hz, 2H), 6 1.95 (m, 2H), 6 1.75 (m, 4H), 6 1.43 (sextet, J = 7.3 Hz, 2H), 6 0.94 (t, J = 7.3 Hz, 3H) MS (Cl) for C24H28N4S m/z 405 (MH+), 282, 241 Example 2 2-butyl-1-[2-(phenylthio)ethyl]-6,7,8,9-tetrahydro-1H-imidazo[4,5-c]quinolin-4-amine hydrochloride NH

N N

S
Part A
A round bottom flask was charged with a magnetic stir bar, 2-(4-amino-2-butyl-6,7,8,9-tetrahydro-lH-imidazo[4,5-c]quinolin-1-yl)ethanol (1.0 g, 3.47 mmol), tert-butyldimethylsilyl chloride (1.62 g, 10.75 mmol), triethylamine (1.58 g, 15.62 mmol), 4-dimethylaminopyridine (0.1 g), and chloroform (30 mL) to give a heterogeneous reaction mixture. The reaction was judged to be complete after stirring at 60 C for 2 hours. The solution was partitioned between ethyl acetate and saturated aqueous ammonium chloride.
The layers were separated and the organic layer was washed with aqueous saturated sodium bicarbonate and brine, dried over anhydrous sodium sulfate, filtered and then concentrated under reduced pressure to afford a 3:1 mixture of 2-butyl- 1 -(2-{[tert-butyl(dimethyl)silyl]oxy}ethyl)-6,7,8,9-tetrahydro-lH-imidazo[4,5-c]quinolin-4-amine and 2-butyl-N-[tent-butyl(dimethyl)silyl]-1-(2-{[tent-butyl(dimethyl)silyl]oxy}ethyl)-6,7,8,9-tetrahydro-1H-imidazo[4,5-c]quinolin-4-amine (1.79 g) as a dark brown oil. The material was used without further purification.
Part B
A round bottom flask was charged with a magnetic stir bar, a 3:1 mixture of 2-butyl-l -(2- { [tent-butyl(dimethyl)silyl]oxy} ethyl)-6,7,8,9-tetrahydro-lH-imidazo[4,5-c]quinolin-4-amine and 2-butyl-N-[tent-butyl(dimethyl)silyl]-1-(2-{[tert-butyl(dimethyl)silyl]oxy} ethyl)-6,7,8,9-tetrahydro-lH-imidazo[4,5-c]quinolin-4-amine (1.6 g) and a 1 M solution of acetic acid in dichloromethane (85 mL) to provide a homogenous solution. The reaction was judged to be complete after stirring at ambient temperature for 30 minutes. The solution was partitioned between chloroform and brine.
The layers were separated and the organic layer was washed with aqueous saturated sodium bicarbonate and brine, dried over anhydrous sodium sulfate, filtered and then concentrated under reduced pressure to afford a dark brown oil. The material was purified by chromatography over silica gel (95/4/1 dichloromethane/methanol/ammonium hydroxide [ 14.8 M in water]) to provide 2-butyl- 1 -(2- { [tert-butyl(dimethyl)silyl]oxy} ethyl)-6,7,8,9-tetrahydro-1H-imidazo[4,5-c]qu nolin-4-amine (1.24 g, 3.10 mmol) as a colorless oil.
Part C
A round bottom flask was charged with a magnetic stir bar, 2-butyl-1-(2-{[tert-butyl(dimethyl)silyl]oxy} ethyl)-6,7,8,9-tetrahydro-lH-imidazo[4,5-c]quinolin-4-amine (0.83 g, 2.06 mmol), di-tert-butyl dicarbonate (1.79 g, 8.24 mmol), triethylamine (0.52 g, 5.15 mmol), 4-dimethylaminopyridine (0.1 g), and anhydrous tetrahydrofuran (21 mL) under a nitrogen atmosphere. The reaction mixture was heated to 60 C to give a homogeneous solution that was maintained at 60 C for 2.5 hours at which time the reaction was judged to be complete. The solution was cooled to ambient temperature and a 1 M solution of tetrabutylammonium fluoride in tetrahydrofuran (2.27 mL, 2.27 mmol) was added. The reaction was judged to be complete after stirring at ambient temperature for 30 minutes. The solution was partitioned between ethyl acetate and saturated aqueous ammonium chloride. The layers were separated. The organic layer was washed with saturated aqueous sodium bicarbonate and brine, dried over anhydrous sodium sulfate, filtered and then concentrated under reduced pressure to afford a light yellow solid. The material was purified by chromatography over silica gel (95/5 dichloromethane/methanol) to provide di(tert-butyl) 2-butyl-l-(2-hydroxyethyl)-6,7,8,9-tetrahydro-lH-imidazo[4,5-c] quinolin-4-ylimidodicarbonate (0.55 g, 1.13 mmol) as a clear gum.
Part D
A round bottom flask was charged with a magnetic stir bar, di(tert-butyl) 2-butyl-1-(2-hydroxyethyl)-6,7,8,9-tetrahydro-lH-imidazo[4,5-c]quinolin-4-ylimidodicarbonate (0.55 g, 1.13 mmol) and anhydrous dichloromethane (11 mL) under a nitrogen atmosphere. The resulting homogeneous solution was cooled to -10 C in a methanol/ice bath. To the cooled solution was added triethylamine (0.23 g, 2.26 mmol) and methanesulfonyl chloride (0.19 g, 1.70 mmol). The reaction was judged to be complete after stirring at -10 C for 15 minutes and was then partitioned between ethyl acetate and saturated aqueous ammonium chloride. The layers were separated. The organic layer was washed with saturated aqueous sodium bicarbonate and brine, dried over anhydrous sodium sulfate, filtered and then concentrated under reduced pressure to afford 2-{4-[bis(tert-butoxycarbonyl)amino]-2-butyl-6,7,8,9-tetrahydro-lH-imidazo[4,5-c]quinolin-l-yl}ethyl methanesulfonate (0.61 g, 1.08 mmol) as a gummy yellow solid. The material was used without further purification. MS (CI) for C27H42N407S m/z 567 (MH+), 467, 367, 271.
Part E
A round bottom flask was charged with a magnetic stir bar, 2-{4-[bis(tert-butoxycarbonyl)amino]-2-butyl-6,7,8,9-tetrahydro-lH-imidazo[4,5-c]quinolin-l -yl} ethyl methanesulfonate (0.61 g, 1.08 mmol), benzenethiol (0.21 g, 1.88 mmol), triethylamine (0.25 g, 2.43 mmol) and anhydrous dimethyl formamide (11 mL) under a nitrogen atmosphere. The reaction mixture was heated to 80 C to give a dark yellow, homogeneous solution that was maintained at 80 C for 2.5 hours at which time the reaction was judged to be complete. The solution was cooled and then partitioned between ethyl acetate and saturated aqueous sodium bicarbonate. The layers were separated. The organic layer was washed with saturated aqueous sodium bicarbonate and brine, dried over anhydrous sodium sulfate, filtered and then concentrated under reduced pressure to afford a yellow oil. The material was purified by chromatography over silica gel (95/5 dichloromethane/methanol) to provide di(tert-butyl) 2-butyl- 1 -[2-(phenylthio)ethyl]-6,7,8,9-tetrahydro-lH-imidazo[4,5-c]quinolin-4-ylimidodicarbonate (0.54 g, 0.93 mmol) as a light yellow oil. MS (CI) for C32H44N4O4S m/z 581 (MH+), 481, 381, 245.
Part F
A round bottom flask was charged with a magnetic stir bar, di(tert-butyl) 2-butyl-1-[2-(phenylthio)ethyl] -6, 7, 8,9-tetrahydro-lH-imidazo[4,5-c]quinolin-4-ylimidodicarbonate (0.50 g, 0.86 mmol), a 4 M solution of hydrochloric acid in dioxane (5 mL), and dichloromethane (5 mL). The reaction was judged to be complete after stirring at ambient temperature for 2 hours. The volatiles were removed under reduced pressure to afford an off white solid. The material was recrystallized from acetonitrile to provide 2-butyl- 1-[2-(phenylthio)ethyl]-6,7,8,9-tetrahydro-1H-imidazo[4,5-c]quinolin-4-amine hydrochloride (0.17 g, 1.30 mmol) as fluffy white needles, m.p. 237-238 C.
Analysis.

Calculated for C22H28N4S =(H2O)114 = (HCl)2: %C 57.70; %H, 6.71; %N, 12.23.
Found %C
57.62; %H, 6.57; %N, 12.41 'H-NMR (300 MHz, DMSO) 6 7.81 (bs, 2H), 6 7.22-7.39 (m, 5H), S 4.64 (t, J =
6.8 Hz, 2H), 6 3.40 (t, J = 6.8 Hz, 2H), 6 2.75 (m, 6H), S 1.71 (m, 6H), S 1.34 (sextet, J = 7.3 Hz, 2H), 8 0.89 (t, J = 7.3 Hz, 3H) MS (CI) for C22H28N4S (H20)114 (HCl)2 m/z 381 (MH+), 245, 137 Example 3 2-butyl-l -[4-(phenylsulfonyl)butyl]-1H-imidazo[4,5-c]quinolin-4-amine N N
N
O=S=O

\
Part A
Using the general method of Example 1 Part E, 2-butyl-1-(4-{[tert-butyl(dimethyl)silyl]oxy}butyl)-1H-imidazo[4,5-c]quinoline (16.0 g, 38.87 mmol) was oxidized to 2-butyl-l-(4-{[tent-butyl(dimethyl)silyl]oxy}butyl)-1H-imidazo[4,5-c]quinoline-5N-oxide (16.61 g, 38.87 mmol) which was isolated without purification as a tan solid.
Part B

A round bottom flask was charged with a magnetic stir bar, 2-butyl-1-(4-{[tert-butyl(dimethyl)silyl]oxy}butyl)-1H-imidazo[4,5-c]quinoline-5N-oxide (16.61 g, 38.87 mmol), a 14.8 M solution of ammonium hydroxide in water (75 mL) and chloroform (200 mL). To the rapidly stirring solution was addedp-toluenesulfonyl chloride (8.15 g, 42.76 mmol) in a portion wise fashion resulting in a mild exotherm. The reaction was judged to be complete after stirring at ambient temperature for 10 minutes. The solution was partitioned between chloroform and aqueous saturated sodium bicarbonate. The layers were separated. The organic layer was washed with saturated aqueous sodium bicarbonate and brine, dried over anhydrous sodium sulfate, filtered and then concentrated under reduced pressure to afford an off-white solid. The material was triturated with ethyl ether and collected by filtration to provide 2-butyl-l-(4-{[tent-butyl(dimethyl)silyl]oxy}butyl)-1H-imidazo[4,5-c]quinolin-4-amine (9.3 g, 21.80 mmol) as a fine white powder.
The material was used without further purification.
Part C
A round bottom flask was charged with a magnetic stir bar, 2-butyl-1-(4-{[tert-butyl(dimethyl)silyl]oxy}butyl)-1H-imidazo[4,5-c]quinolin-4-amine (9.2 g, 21.56 mmol), a 1M solution of tetrabutylammonium fluoride in tetrahydrofuran (23.72 mL, 23.72 mmol), and anhydrous tetrahydrofuran (100 mL) to give a homogeneous, light orange solution. The reaction was judged to be complete after stirring at ambient temperature for 1 hour. While stirring, water (100 mL) was added and resulted in a mild exotherm. The volatiles were removed under reduced pressure until a solid precipitated out of solution.
The solid was collected by filtration and washed with water (20 mL) and acetone (20 mL) to afford a white solid. The material was triturated with ethyl ether (50 mL) and collected by filtration to provide 4-(4-amino-2-butyl-lH-imidazo[4,5-c]quinolin-1-yl)butan-l-ol (6.12 g, 19.59 mmol) as a fine white solid, m.p. 184-186 C.
Analysis. Calculated for C18H24N40: %C 69.20; %H, 7.74; %N, 17.93. Found %C
69.05;
%H, 8.02; %N, 18.03 MS (CI) for C 18H24N40 m/z 313 (MH+) Part D
A round bottom flask was charged with a magnetic stir bar, 4-(4-amino-2-butyl-1 H-imidazo[4,5-c]quinolin-1-yl)butan-l-ol (7.3 g, 23.37 mmol), triethylamine (3.55 g, 35.06 mmol), and anhydrous dimethyl formamide (93 mL) under a nitrogen atmosphere.
To the stirred solution was added phosphorus oxychloride (3.94 g, 25.70 mmol) in a drop wise fashion resulting in an exotherm to give a dark yellow heterogeneous reaction mixture. The reaction mixture was heated to 60 C to give a homogeneous solution that was maintained at 60 C for 5 hours at which time the starting material was completely consumed. The volatiles were removed under reduced pressure to give a dark brown oil.
The material was partitioned between chloroform and saturated aqueous sodium bicarbonate. The layers were separated and the aqueous layer was extracted with chloroform (lx). The organic layers were combined and the volatiles removed under reduced pressure to afford a 2:1 mixture ofN-[2-butyl-l-(4-chlorobutyl)-1H-imidazo[4,5-c]quinolin-4-yl]-N,N-dimethylimidoformamide and 2-butyl-l-(4-chlorobutyl)-1H-imidazo[4,5-c]quinolin-4-amine (7.70 g) as an off-white solid. The material was used without further purification.
Part E
A round bottom flask was charged with a magnetic stir bar, a 2:1 mixture of N-[2-butyl- l -(4-chlorobutyl)-1 H-imidazo [4, 5-c]quinolin-4-yl]-N,N-dimethylimidoformamide and 2-butyl-l-(4-chlorobutyl)-1H-imidazo[4,5-c]quinolin-4-amine (1.3 g), benzenesulfinic acid sodium salt (1.67 g, 10.11 mmol), and anhydrous dimethyl formamide (15 mL) under a nitrogen atmosphere. The resulting solution was heated to 100 C to give a homogeneous solution that was maintained at 100 C for 90 hours at which time the starting materials were completely consumed. The solution was cooled and then partitioned between chloroform and water. The layers were separated. The organic layer was washed with saturated aqueous sodium bicarbonate and brine, dried over anhydrous sodium sulfate, filtered and then concentrated under reduced pressure to afford a dark yellow gum. The material was dissolved in methanol (20 mL) and a 4 M solution of hydrochloric acid in dioxane (3.02 mL, 12.1 mmol). The light orange solution was stirred at ambient temperature for 12 hours at which time the reaction was judged to be complete.
The volatiles were removed under reduced pressure to give a light yellow gum.
The material was partitioned between chloroform and saturated aqueous sodium bicarbonate.
The layers were separated and the aqueous layer was extracted with chloroform (lx). The organic layers were combined, washed with brine, dried over anhydrous sodium sulfate, filtered and then concentrated under reduced pressure to afford a light yellow solid. The material was purified by chromatography over silica gel (95/5 dichloromethane/methanol) to give an off-white solid. The solid (0.63 g) was dissolved in ethyl acetate (50 mL) and brought to reflux. Activated charcoal (0.6 g) was added and the resulting mixture was heated at reflux for 5 minutes. The charcoal was removed by filtration through fluted paper to provide a colorless solution. The solution was concentrated under reduced pressure to give a solid that was recrystallized from ethyl acetate and hexanes to provide 2-butyl-l-[4-(phenylsulfonyl)butyl]-IH-imidazo[4,5-c]quinolin-4-amine (0.37 g, 0.85 mmol) as a white fluffy solid, m.p. 179-180 C. Analysis. Calculated for C24H28N402S:
%C 66.03; %H, 6.46; %N, 12.83. Found %C 65.88; %H, 6.49; %N, 12.76 'H-NMR (300 MHz, DMSO) 6 7.98 (d, J = 8.3 Hz, 1H), 8 7.82 (m, 2H) 8 7.73 (d, J
= 7.3 Hz, 1H), 5 7.62 (m, 3H) 8 7.41 (t, J = 7.6 Hz, 1H), 6 7.22 (t, J = 7.6 Hz, 1H), 8 6.45 (bs, 2H), 6 4.51 (t, J = 7.3 Hz, 2H), 5 3.90 (t, J = 7.8 Hz, 211), 8 2.86 (t, J =
7.6 Hz, 3H), 6 1.69-1.90 (m, 6H), 6 1.43 (sextet, J = 7.3 Hz, 2H), 8 0.95 (t, J = 7.3 Hz, 3H) MS (CI) for C24H28N402S m/z 437 (MH+), 295 Example 4 2-butyl-1 [4-(methylthio)butyl]-lH-imidazo[4,5-c]quinolin-4-amine N N
N

S
Part A
A round bottom flask was charged with a magnetic stir bar, a 2:1 mixture of N-[2-butyl- l -(4-chlorobutyl)-1 H-imidazo [4, 5 -c] quinolin-4-yl]-N,N-dimethylimidoformamide and 2-butyl-l-(4-chlorobutyl)-1H-imidazo[4,5-c]quinolin-4-amine (6.17 g), a 4 M solution of hydrochloric acid in dioxane (21.15 mL, 84.56 mmol), and methanol (200 mL) to provide a light orange solution. The reaction was judged to be complete after stirring at ambient temperature for 43 hours. The volatiles were removed under reduced pressure and the resulting light yellow solid was partitioned between chloroform and saturated aqueous sodium bicarbonate. The layers were separated and the aqueous layer was extracted with chloroform (lx). The organic layers were combined, dried over anhydrous sodium sulfate, filtered and then concentrated under reduced pressure to afford 2-butyl-1-(4-chlorobutyl)-lH-imidazo[4,5-c]quinolin-4-amine (4.65 g, 14.05 mmol) as an off-white solid. The material was used without further purification. MS (CI) for C18H23C1N4 m/z 331 (MH+), 295.
Part B
A round bottom flask was charged with a magnetic stir bar, 2-butyl-1-(4-chlorobutyl)-1H-imidazo[4,5-c]quinolin-4-amine (1.5 g, 4.53 mmol), sodium thiomethoxide (0.48 g, 6.80 mmol), and anhydrous dimethyl formamide (18 mL) under a nitrogen atmosphere, The reaction mixture was heated to 60 C to give a homogeneous solution that was maintained at 60 C for 16 hours at which time the starting material was completely consumed. The solution was cooled and then partitioned between chloroform and water. The layers were separated and the organic layer was washed with saturated aqueous sodium bicarbonate. The combined aqueous layers were extracted with chloroform (lx). The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered and then concentrated under reduced pressure to afford a dark brown oil. The material was purified by chromatography over silica gel (90/10 dichloromethane/methanol) to provide a light yellow solid. The solid was recrystallized from dimethyl forinamide and water to give 2-butyl-l-[4-(methylthio)butyl]-1H-imidazo[4,5-c]quinolin-4-amine (0.83 g, 2.42 mmol) as light yellow needles, m.p. 127-130 C.

Analysis. Calculated for C19H26N4S: %C 66.63; %H, 7.65; %N, 16.36. Found %C
66.68;
%H, 7.53; %N, 16.35 1H-NMR (500 MHz, DMSO) 8 8.04 (d, J = 8.3 Hz, 1H), S 7.61 (d, J = 8.3 Hz, 1H), 8 7.41 (t, J = 8.3 Hz, 1H), 8 7.25 (t, J = 8.3 Hz, 1H), 6 6.43 (bs, 2H), 8 4.52 (t, J
= 7.6 Hz, 2H), 8 2.92 (t, J = 7.8 Hz, 2H), 8 2.53 (t, J = 7.3 Hz, 2H), 8 2.01 (s, 3H), 6 1.90 (m, 2H) 8 1.80 (p, J = 7.8 Hz, 2H) 6 1.71 (p, J = 7.3 Hz, 2H) 8 1.46 (sextet, J = 7.3 Hz, 2H), 6 0.96 (t, J = 7.3 Hz, 3H) MS (CI) for C19H26N4S m/z 343 (MH+), 295, 241 Example 5 2-butyl-l -[4-(methylsulfonyl)butyl]-1H-imidazo[4,5-c]quinolin-4-amine N ~ N
I

6O=S=O
Part A
A round bottom flask was charged with a magnetic stir bar, 2-butyl-l-[4-(methylthio)butyl]-1H-imidazo[4,5-c]quinolin-4-amine (1.2 g, 3.50 mmol), and chloroform (18 mL). Solid 3-chloroperbenzoic acid (1.72 g, 7.71 mmol) was added to the resulting solution portion wise over 15 minutes. The reaction was judged to be complete after stirring at ambient temperature for 5 minutes. The solution was partitioned between chloroform and 1% aqueous sodium carbonate. The layers were separated and the organic layer was washed with brine, dried over anhydrous sodium sulfate, filtered and then concentrated under reduced pressure to afford a light brown solid. The material was purified by chromatography over silica gel (90/10 dichloromethane/methanol) to provide an off-white solid. The solid was recrystallized from acetonitrile and water to give 2-butyl-l-[4-(methylsulfonyl)butyl]-1H-imidazo[4,5-c]quinolin-4-amine (0.61 g, 1.63 mmol) as off-white needles, m.p. 164-165 C.
Analysis. Calculated for C19H26N402S: %C 60.94; %H, 7.00; %N, 14.96. Found %C
60.71; %H, 6.94; %N, 14.94 1H-NMR (300 MHz, DMSO) 6 8.03 (d, J = 8.3 Hz, 1H), 6 7.61 (d, J = 8.3 Hz, 1H), 8 7.42 (t, J = 8.3 Hz, 1H), 8 7.26 (t, J = 8.3 Hz, 1H), 6 6.46 (bs, 2H), S 4.56 (t, J
= 7.6 Hz, 2H), 6 3.21 (t, J = 7.3 Hz, 2H), 6 2.96 (s, 3H), 6 2.93 (t, J = 7.8 Hz, 2H), 6 1.91 (m, 4H), 6 1.81 (p, J = 7.3 Hz, 2H), 8 1.45 (sextet, J = 7.3 Hz, 2H), 8 0.96 (t, J = 7.3 Hz, 3H) MS (CI) for C19H26N402S m/z 375 (MH+), 295 Example 6 1-[2-(phenylthio)ethyl]-1H-imidazo[4,5-c]quinolin-4-amine N N
N

S
Part A
A round bottom flask was charged with a magnetic stir bar, 2-(4-amino-lH-imidazo[4,5-c]quinolin-1-yl)ethanol (8.46 g, 37.06 mmol), and thionyl chloride (68.99 g, 57.99 mmol) under a nitrogen atmosphere. The reaction mixture was heated to 80 C to give a heterogeneous reaction mixture that was maintained at 80 C for 2 hours at which time the starting material was completely consumed. The solution was cooled and quenched by the addition of water (400 mL). To the stirred solution was added solid sodium carbonate until the pH reached 10 at which time a solid precipitated out of solution. The solid was collected by filtration to afford 1-(2-chloroethyl)-1H-imidazo[4,5-c]quinolin-4-amine (7.86 g, 31.86 mmol) as an off-white solid. The material was used without further purification.
Part B
A round bottom flask was charged with a magnetic stir bar, 1-(2-chloroethyl)-imidazo[4,5-c]quinolin-4-amine (2.0 g, 8.11 mmol), sodium benzenethiolate (1.79 g, 12.16 mmol), and anhydrous dimethyl sulfoxide (40 mL) under a nitrogen atmosphere.
The reaction mixture was heated to 100 C to give a homogeneous solution that was maintained at 100 C for 30 minutes at which time the starting material was completely consumed. The hot solution was poured into rapidly stirred water (300 mL) which caused a solid to precipitate out of solution. The solid was collected by filtration to afford an off-white solid. The material was triturated with acetonitrile and collected by filtration to give 1-[2-(phenylthio)ethyl]-1H-imidazo[4,5-c]quinolin-4-amine (2.08 g, 6.49 mmol) as an off-white powder, in. p. 233-235 C.

Analysis. Calculated for C18H16N4S: %C 67.47; %H, 5.03; %N, 17.49. Found: %C
67.20;
%H, 4.95; %N, 17.52 1H-NMR (300 MHz, DMSO) 5 8.14 (s, 1H), 6 7.76 (d, J = 8.3 Hz, 1H), S 7.60 (t, J = 8.3 Hz, 1H), 6 7.28-7.44 (m, 6H), 6 7.12 (t, J = 8.3 Hz, 1H), 6 6.58 (bs, 2H), 6 4.79 (t, J = 6.8 Hz, 2H), 6 3.48 (t, J = 6.8 Hz, 2H) MS (CI) for C18H16N4S m/z 321 (MH), 185, 137 Example 7 1-[4-(phenylsulfonyl)butyl]-1H-imidazo[4,5-c]quinolin-4-amine N N\>
N

O=S=O

Part A
A round bottom flask was charged with a magnetic stir bar, N,N-dibenzyl-1H-imidazo[4,5-c]quinolin-4-amine (20.0 g, 55.04 mmol), sodium hydride (3.3 g, 60%
dispersion, 82.56 mmol), and anhydrous dimethyl formamide (275 mL) under a nitrogen atmosphere. After the reaction mixture had stirred at ambient temperature for 2 hours, 4-chloro-1-iodobutane (19.23 g, 88.06 mmol) was added and the resulting homogeneous solution was stirred at ambient temperature for 48 hours at which time the starting material was consumed. The solution was partitioned between ethyl acetate and water.
The layers were separated and the organic layer was washed with saturated aqueous sodium bicarbonate and brine, dried over anhydrous sodium sulfate, filtered and then concentrated under reduced pressure to afford a light yellow solid. The material was recrystallized from ethyl acetate and hexanes to give N,N-dibenzyl-l-(4-chlorobutyl)-IH-imidazo[4,5-c]quinolin-4-amine (20.7 g, 45.49 mmol) as white needles. MS (CI) for C28H27C1N4 m/z 455 (MH+), 365, 329, 239 Part B
A round bottom flask was charged with a magnetic stir bar, N,N-dibenzyl-1-(4-chlorobutyl)- 1H-imidazo[4,5-c]quinolin-4-amine (7.0 g, 15.38 mmol), sodium benzenethiolate (3.46 g, 26.15 mmol), and anhydrous dimethyl formamide (77 mL) under a nitrogen atmosphere. The reaction mixture was heated to 60 C to give a heterogeneous mixture that was maintained at 60 C for 4 hours at which time the starting material was completely consumed. The cooled solution was partitioned between ethyl acetate and water. The layers were separated. The organic layer was washed with saturated aqueous sodium bicarbonate and brine, dried over anhydrous sodium sulfate, filtered and then concentrated under reduced pressure to afford a colorless oil. The material was purified by chromatography over silica gel (80/20 hexanes/ethyl acetate) to provide N,N-dibenzyl-1-[4-(phenylthio)butyl]-1H-imidazo[4,5-c]quinolin-4-amine (7.5 g, 14.19 mmol) as a colorless oil. MS (CI) for C34H32N4S m/z 529 (MH+), 439, 349 Part C
A round bottom flask was charged with a magnetic stir bar, N,N-dibenzyl-l-[4-(phenylthio)butyl]-1H-imidazo[4,5-c]quinolin-4-amine (3.64 g, 6.88 mmol) and chloroform (34 mL). Solid 3-chloroperbenzoic acid (3.39 g, 15.14 mmol) was added portion wise to the resulting solution over 5 minutes. The reaction was judged to be complete after stirring at ambient temperature for 5 minutes. The solution was partitioned between chloroform and 1 % aqueous sodium carbonate. The layers were separated. The organic layer was washed with brine, dried over anhydrous sodium sulfate, filtered and then concentrated under reduced pressure to afford a red gum. The material was purified by chromatography over silica gel (dichloromethane) to provide N,N-dibenzyl-1-[4-(phenylsulfonyl)butyl]-1H-imidazo[4,5-c]quinolin-4-amine '(2.85 g, 5.08 mmol) as a light pink gum. MS (CI) for C34H32N402S m/z 561 (MH+), 471, 381 Part D
A round bottom flask was charged with a magnetic stir bar, N,N-dibenzyl-1-[4-(phenylsulfonyl)butyl]-1H-imidazo[4,5-c]quinolin-4-amine (1.0 g, 1.78 mmol), triflic acid (2.68 g, 17.83 mmol), and anhydrous dichloromethane (14 mL) under a nitrogen atmosphere. The reaction was judged to be complete after stirring at ambient temperature for 24 hours. The solution was partitioned between chloroform and excess aqueous sodium hydroxide (20%). The layers were separated. The aqueous layer was extracted with chloroform (3x). The organic layers were combined and then concentrated under reduced pressure to afford a light brown solid. The material was purified by chromatography over silica gel (90/10 dichloromethane/methanol) to provide a fine white powder which was recrystallized from acetonitrile to give 1-[4-(phenylsulfonyl)butyl]-1H-imidazo[4,5-c]quinolin-4-amine (0.32 g, 0.84 mmol) as white needles, in. p.
175-177 C.
Analysis. Calculated for C2oH2ON402S: %C 63.14; %H, 5.30; %N, 14.73. Found: %C
63.14; %H, 5.24; %N, 14.77 'H-NMR (300 MHz, DMSO) 8 8.15 (s, 1H), S 8.01 (d, J = 8.3 Hz, 1H), 8 7.80 (m, 2H), 8 7.71 (m, 1H), 6 7.60 (m, 3H), 6 7.44 (t, J = 8.3 Hz, 1H), 6 7.24 (t, J = 8.3 Hz, 1H), 8 6.59 (bs, 2H), 8 4.59 (t, J = 6.8 Hz, 2H), 5 3.38 (t, J = 7.8 Hz, 2H), 6 1.93 (m, 2H), 6 1.58 (m, 2H) MS (CI) for C2oH2oN402S m/z 381 (MH+), 239 Example 8 1-[4-(methylsulfonyl)butyl]-1H-imidazo[4,5-c]quinolin-4-amine NHZ
N N>

N

O=S=O
Part A
Using the general method of Example 7 Part B, N,N-dibenzyl-1-(4-chlorobutyl)-1H-imidazo[4,5-c]quinolin-4-amine (5.0 g, 10.99 mmol) was converted to N,N-dibenzyl-1-[4-(methylthio)butyl]-1H-imidazo[4,5-c]quinolin-4-amine using sodium thiomethoxide (1.16 g, 16.48 mmol). The material was purified by chromatography over silica gel (80/20 hexanes/ethyl acetate) to provide the product (4.91 g, 10.52 mmol) as a colorless oil. MS
(Cl) for C29H30N4S m/z 467 (MH+), 377, 287, 185 Part B
Using the general method of Example 7 Part C, N,N-dibenzyl-1-[4-(methylthio)butyl]-1H-imidazo[4,5-c]quinolin-4-amine (4.91 g, 15.52 mmol) was oxidized to N,N-dibenzyl-l-[4-(methylsulfonyl)butyl]-1H-imidazo[4,5-c]quinolin-4-amine which was purified by chromatography over silica gel (80/20 hexanes/ethyl acetate) to provide the product (4.53 g, 9.08 mmol) as a light orange solid. MS (CI) for C29H30N402S m/z 499 (MH+), 409, 319 Part C
Using the general method of Example 7 Part D, N,N-dibenzyl-l-[4-(methylsulfonyl)butyl]-1H-imidazo[4,5-c]quinolin-4-amine (4.53 g, 9.08 mmol) was converted to 1-[4-(methylsulfonyl)butyl]-1H-imidazo[4,5-c]quinolin-4-amine.
The material was recrystallized from methanol and water to afford the title compound (1.33 g, 4.18 mmol) as white needles, m.p. 203-204 C.
Analysis. Calculated for C15H18N402S: %C 56.58; %H, 5.70; %N, 17.60. Found: %C
56.33; %H, 5.63; %N, 17.41 'H-NMR (300 MHz, DMSO) S 8.22 (s, 1H), S 8.06 (d, J = 8.3 Hz, 1H), 6 7.62 (d, J = 8.3 Hz, I H), S 7.45 (t, J = 8.3 Hz, I H), b 7.27 (t, J = 8.3 Hz, I H), 6 6.59 (bs, 2H), b 4.65 (t, J =
6.8 Hz, 2H), b 3.19 (t, J = 7.8 Hz, 2H), 6 2.93 (s, 3H), S 1.99 (m, 2H), S
1.74 (m, 2H) MS (CI) for C15H18N402S m/z 319 (MH+), 239 Example 9 1-[4-(phenylthio)butyl]-lH-imidazo[4,5-c]quinolin-4-amine N N
N

S
Part A
Using the general method of Example 1 Part D, N-(4-{[tert-butyl(dimethyl)silyl]oxy}butyl)quinoline-3,4-diamine (101.21 g, 292.90 mmol) was cyclized to 1-(4-{[tert-butyl(dimethyl)silyl]oxy}butyl)-1H-imidazo[4,5-c]quinoline using triethyl orthoformate (65.11 g, 439.35 mmol). The product (75.0 g, 210.93 mmol) was isolated as a brown oil and used without further purification.

Part B
Using the general method of Example 1 Part E, 1-(4- { [tert-butyl(dimethyl)silyl]oxy}butyl)-1H-imidazo[4,5-c]quinoline (42.2 g, 118.69 minol) was oxidized to 1-(4-{[tert-butyl(dimethyl)silyl]oxy}butyl)-1H-imidazo[4,5-c]quinoline-5N-oxide (44.10 g, 118.69 mmol) which was isolated without further purification as a tan solid.
Part C
Using the general method of Example 3 Part B, 1-(4-{[tert-butyl(dimethyl)silyl]oxy}butyl)-1H-imidazo[4,5-c]quinoline-5N-oxide (44.10 g, 118.69 mmol) was aminated to provide 1-(4-{[tent-butyl(dimethyl)silyl]oxy}butyl)-lH-imidazo[4,5-c] quinolin-4-amine. The material was triturated with ethyl ether and collected by filtration to afford the product (21.54 g, 58.12 mmol) as a light brown solid which was used without further purification.
Part D
Using the general method of Example 3 Part C, 1-(4-{[tert-butyl(dimethyl)silyljoxy}butyl)-1H-imidazo[4,5-c]quinolin-4-amine (21.5 g, 58.02 mmol) was converted to 4-(4-amino-lH-imidazo[4,5-c]quinolin-1-yl)butan-l-ol. The material was triturated with cold methanol (0 C) and collected by filtration to afford the product (13.92 g, 54.30 mmol) which was used without further purification. MS (CI) for C14Hi6N4O m/z 257 (MH+), 185 Part E
Using the general method of Example 6 Part A, 4-(4-amino-lH-imidazo[4,5-c] quinolin- 1 -yl)butan- 1 -ol (5.0 g, 19.51 mmol) was chlorinated to provide 1-(4-chlorobutyl)- 1H-imidazo[4,5-c]quinolin-4-amine (4.92 g, 17.91 mmol) which was isolated without further purification as an off-white solid.
Part F
Using the general method of Example 6 Part B, except that the reaction temperature was lowered to 80 C, 1-(4-chlorobutyl)-lH-imidazo[4,5-c]quinolin-4-amine (1.5 g, 5.46 mmol) was converted to 1-[4-(phenylthio)butyl]-IH-imidazo[4,5-c]quinolin-4-amine. The resulting solid (1.53 g) was dissolved in acetonitrile (90 mL) and brought to reflux. Activated charcoal (0.9 g) was added and the resulting mixture was heated at reflux for 5 minutes and then the charcoal was removed by filtration through fluted paper to provide a colorless solution. The title compound (0.86 g, 2.47 mmol) was isolated as white needles, m.p 158-160 C.
Analysis. Calculated for C20H2ON4S: %C 68.94; %H, 5.79; %N, 16.08. Found: %C
68.70;
%H, 5.74; %N, 16.08 1H-NMR (300 MHz, DMSO) S 8.18 (s, 1H), 6 8.05 (d, J = 8.3 Hz, 1H), 6 7.63 (d, J = 8.3 Hz, 1H), S 7.45 (t, J = 8.3 Hz, 1H), 6 7.26 (m, 5H), 6 7.14-7.19 (m, 1H), S
6.60 (bs, 2H), 6 4.62 (t, J = 6.8 Hz, 2H), S 3.00 (t, J = 7.3 Hz, 2H), 6 2.00 (m, 2H), S 1.61 (m, 2H) MS (Cl) for C20H2ON4S m/z 349 (MH), 185 Example 10 1-[4-(methylthio)butyl]-1H-imidazo[4,5-c]quinolin-4-amine N N\\
N/

S
Part A

Using the general method of Example 6 Part B, except that the reaction temperature was lowered to 80 C, 1-(4-chlorobutyl)-1H-imidazo[4,5-c]quinolin-4-amine (1.5 g, 5.46 mmol) was converted to 1-[4-(methylthio)butyl]-1H-imidazo[4,5-c]quinolin-4-amine using sodium thiomethoxide (0.88 g, 12.56 mmol) in lieu of sodium benzenethiolate. The resulting solid (1.26 g) was dissolved in acetonitrile (40 mL) and brought to reflux. Activated charcoal (0.7 g) was added, the resulting mixture was heated at reflux for 5 minutes and then the charcoal was removed by filtration through fluted paper to provide a colorless solution. The solution was concentrated under reduced pressure to give a solid that was recrystallized from acetonitrile. The title compound (0.66 g, 2.30 mmol) was isolated as white needles, m.p 163-164 C.
Analysis. Calculated for C15H18N4S: %C 62.91; %H, 6.34; %N, 19.56. Found: %C
62.70;
%H, 6.19; %N, 19.45 'H-NMR (300 MHz, DMSO) 6 8.21 (s, 1H), S 8.06 (d, J = 8.3 Hz, 1H), 6 7.62 (d, J = 8.3 Hz, 1 H), 8 7.44 (t, J = 8.3 Hz, 1 H), S 7.26 (t, J = 8.3 Hz, 1 H), 6 6.59 (bs, 2H), 6 4.62 (t, J =
7.6 Hz, 2H), 6 2.50 (t, J = 6.8 Hz, 2H), 6 1.99 (s, 3H), 6 1.95 (p, J = 7.3 Hz, 2H), 6 1.59 (p, J = 7.3 Hz, 2H) MS (CI) for C15H18N4S m/z 287 (MH+), 185 Example 11 2-butyl-l -[5-(methylsulfonyl)pentyl]-lH-imidazo[4,5-c]quinolin-4-amine NHz N N
I

N

O
,S~
Part A

Using the general method of Example 1 Part A, 4-chloro-3-nitroquinoline (107.7 g, 525.87 mmol) was converted to 5-[(3-nitroquinolin-4-yl)amino]pentan-l-ol using amino- 1 -pentanol (79.82 g, 788.81 mmol) in lieu of 4-amino-butanol. The product (117.22 g, 425.77 mmol) was used without further purification as a dark yellow solid. MS
(CI) for C14H17N303 m/z 276 (MH+), 224 Part B

A round bottom flask was charged with a magnetic stir bar, 5-[(3-nitroquinolin-yl)amino]pentan-l-ol (5.0 g, 18.16 mmol), and thionyl chloride (40.78 g, 0.34 mmol) under a nitrogen atmosphere. The reaction mixture was heated to 80 C to give a homogeneous solution that was maintained at 80 C for 1 hour at which time the starting material was completely consumed. The volatiles were removed under reduced pressure and the resulting oil stirred in water made basic (pH 10) with solid sodium carbonate. The resulting solid was collected by filtration to afford N-(5-chloropentyl)-3-nitroquinolin-4-amine (4.80 g, 16.34 mmol) which was used without further purification.

Part C
Using the general method of Example 6 Part B, except that the reaction temperature was lowered to 80 C, N-(5-chloropentyl)-3-nitroquinolin-4-amine (4.75 g, 16.17 mmol) was converted to N-[5-(methylthio)pentyl]-3-nitroquinolin-4-amine using sodium thiomethoxide (1.43 g, 19.40 mmol) in lieu of sodium benzenethiolate.
The product (3.28 g, 10.74 mmol) was isolated without further purification as a light yellow solid. MS (CI) for C15H19N3O2S m/z 306 (MH+), 272, 117 Part D
Using the general method of Example 1 Part C, N-[5-(methylthio)pentyl]-3-nitroquinolin-4-amine (3.20 g, 10.48 mmol) was reduced to N4-[5-(methylthio)pentyl]quinoline-3,4-diamine (2.89 g, 10.48 mmol) which was isolated without further purification as a brown oil.
Part E
Using the general method of Example 1 Part D, N4-[5-(methylthio)pentyl]quinoline-3,4-diamine (2.89 g, 10.48 mmol) was cyclized to provide 2-butyl-l-[5-(methylthio)pentyl]-1H-imidazo[4,5-c]quinoline. The material was purified by chromatography over silica gel (ethyl acetate) to afford the product (2.10 g, 6.15 mmol) as a light brown oil.
Part F
A round bottom flask was charged with a magnetic stir bar, 2-butyl-l -[5-(methylthio)pentyl]-1H-imidazo[4,5-c]quinoline (2.1 g, 6.15 mmol) and chloroform (31 mL). Solid 3-chloroperbenzoic acid (4.41 g, 19.68 mmol) was added portion wise to the solution over 10 minutes and the reaction was stirred at ambient temperature for 30 minutes at which time the starting material was completely consumed. The solution was partitioned between chloroform and saturated aqueous sodium bicarbonate. The layers were separated. The organic layer was washed with saturated aqueous sodium bicarbonate and brine, dried over anhydrous sodium sulfate, filtered and then concentrated under reduced pressure to afford 2-butyl-l-[5-(methylsulfonyl)pentyl]-1H-imidazo[4,5-c]quinoline-5N-oxide (2.40 g, 6.15 mmol) as a tan solid. The material was used without further purification.

Part G
Using the general method of Example 3 Part B, 2-butyl-1-[5-(methylsulfonyl)pentyl]-1H-imidazo[4,5-c]quinoline-5N-oxide (2.40 g, 6.15 mmol) was aminated to provide 2-butyl-l-[5-(methylsulfonyl)pentyl]-1H-imidazo[4,5-c]quinolin-4-amine. The resulting solid (2.24 g) was dissolved in acetonitrile (40 mL) and brought to reflux. Activated charcoal (1 g) was added and the resulting mixture was heated at reflux for 5 minutes and then the charcoal was removed by filtration through fluted paper to provide a light brown solution. Upon cooling 2-butyl-l-[5-(methylsulfonyl)pentyl]-1H-imidazo[4,5-c]quinolin-4-amine (0.90 g, 2.32 mmol) was isolated as white needles, m.p.
173-175 C.
Analysis. Calculated for C20H28N402S: %C 61.83; %H, 7.26; %N, 14.42. Found: %C
61.58; %H, 7.27; %N, 14.36 'H-NMR (300 MHz, DMSO) 6 8.01 (d, J = 8.3 Hz, 1H), 6 7.61 (d, J = 8.3 Hz, 1H), 6 7.41 (t, J = 8.3 Hz, 1H), 6 7.26 (t, J = 8.3 Hz, 1H), 6 6.45 (bs, 2H), 6 4.51 (t, J
= 7.6 Hz, 2H), 6 3.10 (t, J = 7.8 Hz, 2H), 6 2.92 (s, 3H), 6 2.92 (t, J = 7.3 Hz, 2H), 6 1.76 (m, 6H), 6 1.54 (m, 2H), 6 1.46 (sextet, J = 7.3 Hz, 2H), 6 0.99 (t, J = 7.3 Hz, 3H) MS (CI) for C20H28N402S m/z 389 (MH+) Example 12 2-methyl-l-[5-(methylsulfonyl)pentyl]-1H-imidazo[4,5-c]quinolin-4-amine C
N N>-N

Part A
Using the general method of Example 1 Part D, IV4-[5-(methylthio)pentyl]quinoline-3,4-diamine (4.53 g, 16.37 mmol) was cyclized to provide 2-methyl-l-[5-(methylthio)pentyl]-1H-imidazo[4,5-c]quinoline using 1,1,1-trimethoxyethane (2.95 g, 24.6 mmol) and pyridine hydrochloride (0.1 g). The material was triturated with ethyl ether and collected by filtration to afford the product (3.78 g, 12.62 mmol) as a light brown solid which was used without further purification.
Part B
Using the general method of Example 11 Part F, 2-methyl-l-[5-(methylthio)pentyl]-lH-imidazo[4,5-c]quinoline (3.78 g, 12.62 mmol) was oxidized to 2-methyl-l-[5-(methylsulfonyl)pentyl]-1H-imidazo[4,5-c]quinoline-5N-oxide (4.38 g, 12.62 mmol) which was isolated as a tan solid and used without purification.
Part C
Using the general method of Example 3 Part B, 2-methyl-l-[5-(methylsulfonyl)pentyl]-IH-imidazo[4,5-c]quinoline-5N-oxide (4.38 g, 12.62 mmol) was aminated to provide 2-methyl-l-[5-(methylsulfonyl)pentyl]-1H-imidazo[4,5-c]quinolin-4-amine. The resulting solid was triturated with acetonitrile and collected by filtration to afford the title compound (0.8 g, 2.31 mmol) as an off-white solid, m.p. 235-240 C.
Analysis. Calculated for C17H22N402S: %C 58.94; %H, 6.40; %N, 16.17. Found: %C
58.77; %H, 6.34; %N, 16.39 'H-NMR (300 MHz, DMSO) 8 8.02 (d, J = 8.3 Hz, 1H), 8 7.60 (d, J = 8.3 Hz, IH), 6 7.41 (t, J = 8.3 Hz, 1H), 8 7.25 (t, J = 8.3 Hz, 1H), 6 6.49 (bs, 2H), 8 4.50 (t, J
= 7.3 Hz, 2H), 6 3.12 (t, J = 7.8 Hz, 2H), 6 2.92 (s, 3H), 6 2.61 (s, 3H), 6 1.86 (m, 2H), 6 1.74 (m, 2H), 6 1.53 (m, 2H) MS (Cl) for C17H22N402S m/z 347 (MH+), 267 Example 13 2-ethyl- l -[5-(methylsulfonyl)pentyl]-1H-imidazo [4, 5-c] quinolin-4-amine NHZ

N
N \\ /
N

,0 ,S"~
Part A
Using the general method of Example 1 Part D,1V4-[5-(methylthio)pentyl]quinoline-3,4-diamine (4.53 g, 16.37 mmol) was cyclized to 2-ethyl-l-[5-(methylthio)pentyl]-1H-imidazo[4,5-c]quinoline using triethyl orthopropionate (4.3 g, 24.56 mmol) and pyridine hydrochloride (0.1 g). The material was triturated with ethyl ether and collected by filtration to afford the product (3.25 g, 10.37 mmol) as an off-white powder which was used without further purification.
Part B
Using the general method of Example 11 Part F, 2-ethyl-1 -[5-(methylthio)pentyl]-1H-imidazo[4,5-c]quinoline (3.25 g, 10.37 mmol) was oxidized to 2-ethyl-l-[5-(methylsulfonyl)pentyl]-1H-imidazo[4,5-c]quinoline-5N-oxide (3.75 g, 10.37 mmol) which was isolated as a tan solid and used without purification.
Part C
Using the general method of Example 3 Part B, 2-ethyl-l-[5-(methylsulfonyl)pentyl]-1H-imidazo[4,5-c]quinoline-5N-oxide (3.75 g, 10.37 mmol) was aminated to provide 2-ethyl-l-[5-(methylsulfonyl)pentyl]-1H-imidazo[4,5-c]quinolin-4-amine. The resulting solid was recrystallized sequentially from ethanol and acetonitrile to afford the title compound (1.4 g, 3.88 mmol) as off-white needles, m.p. 189-191 C.
Analysis. Calculated for C18H24N402S: %C 59.98; %H, 6.71; %N, 15.54. Found: %C
59.71; %H, 6.68; %N, 15.64 'H-NMR (300 MHz, DMSO) 6 8.01 (d, J = 8.3 Hz, 1H), S 7.61 (d, J = 8.3 Hz, 1H), 6 7.42 (t, J = 8.3 Hz, 1H), 6 7.26 (t, J = 8.3 Hz, 1H), 6 6.45 (bs, 2H), 6 4.50 (t, J
= 7.6 Hz, 2H), 6 3.10 (t, J = 7.8 Hz, 2H), 8 2.95 (q, J = 7.3 Hz, 2H), 6 2.92 (s, 3H), 6 1.85 (m, 2H), 8 1.74 (m, 2H), 6 1.55 (m, 2H), 6 1.38 (t, J = 7.3 Hz, 3H) MS (CI) for C18H24N402S m/z 361 (MH+), 281 Example 14 1-[5-(methylsulfonyl)pentyl]-1H-imidazo[4,5-c]quinolin-4-amine N N>
N

,O
,S~
Part A
Using the general method of Example 1 Part D, N4-[5-(methylthio)pentyl]quinoline-3,4-diamine (4.53 g, 16.37 mmol) was cyclized to 1-[5-(methylthio)pentyl]-1H-imidazo[4,5-c]quinoline using triethyl orthoformate (3.64 g, 24.56 mmol) and pyridine hydrochloride (0.1 g). The product (4.05 g, 14.19 mmol) was isolated as a brown oil and used without further purification.
Part B
Using the general method of Example 11 Part F, 1-[5-(methylthio)pentyl]-1H-imidazo[4,5-c]quinoline (4.05 g, 14.19 mmol) was oxidized to 1-[5-(methylsulfonyl)pentyl]-1H-imidazo[4,5-c]quinoline-5N-oxide (4.73 g, 14.19 mmol) which was isolated as a tan solid and used without further purification.
Part C
Using the general method of Example 3 Part B, 1-[5-(methylsulfonyl)pentyl]-1H-imidazo[4,5-c]quinoline-5N-oxide (4.73 g, 14.19 mmol) was aminated to provide 1-[5-(methylsulfonyl)pentyl]-1H-imidazo[4,5-c]quinolin-4-amine. The material was purified by chromatography over silica gel (95/5 dichloromethane/methanol) to afford a light yellow solid. The solid was recrystallized from dimethyl formamide to give the title compound (0.43 g, 1.29 mmol) as a light yellow, granular solid, m.p. 199-201 C.

Analysis. Calculated for C16H2oN402S: %C 57.81; %H, 6.06; %N, 16.85. Found: %C
57.01; %H, 6.06; %N, 16.70 'H-NMR (300 MHz, DMSO) 8 8.20 (S, 1H), 6 8.04 (d, J = 8.3 Hz, 1H), S 7.62 (d, J = 8.3 Hz, 1H), 6 7.44 (t, J = 8.3 Hz, 111), 6 7.27 (t, J = 8.3 Hz, I H), 6 6.57 (bs, 2H), 6 4.61 (t, J =
6.8 Hz, 2H), 6 3.09 (t, J = 7.8 Hz, 2H), 6 2.92 (s, 3H), 6 1.91 (p, J = 7.6 Hz, 2H), 8 1.73 (m, 2H), 6 1.45 (m, 2H) MS (CI) for C16H2oN402S m/z 333 (MH+) Example 15 2-hexyl- l -[5-(methylsulfonyl)pentyl]-1H-imidazo[4,5-c]quinolin-4-amine N N
I
N

,o s Part A
A round bottom flask was charged with a magnetic stir bar, 1V4-[5-(methylthio)pentyl] quinoline-3,4-diamine (3.17 g, 11.46 mmol) and anhydrous pyridine (46 mL) under a nitrogen atmosphere. The resulting homogeneous solution was cooled to 0 C in an ice-water bath. To the cooled solution was added neat heptanoyl chloride (1.87 g, 12.61 mmol). The reaction was judged to be complete after stirring at ambient temperature for 1 hour. The volatiles were removed under reduced pressure and the resulting oil was partitioned between chloroform and water. The layers were separated.
The organic layer was washed with saturated aqueous sodium bicarbonate and brine, dried over anhydrous sodium sulfate, filtered and then concentrated under reduced pressure to afford N-(4-{[5-(methylthio)pentyl]amino }quinolin-3-yl)heptanamide (4.44 g, 11.46 mmol) which was isolated as a brown oil and used without further purification.
Part B
A round bottom flask was charged with a magnetic stir bar, N-(4-{[5-(methylthio)pentyl]amino }quinolin-3-yl)heptanamide (4.44 g, 11.46 mmol), pyridine hydrochloride (0.13 g, 1.15 mmol), and anhydrous pyridine (50 mL) under a nitrogen atmosphere. The reaction was judged to be complete after stirring at reflux for 1.5 hours.
The solution was cooled and partitioned between ethyl acetate and water. The layers were separated. The organic layer was washed with saturated aqueous sodium bicarbonate and brine, dried over anhydrous sodium sulfate, filtered and then concentrated under reduced pressure to afford 2-hexyl-l-[5-(methylthio)pentyl]-1H-imidazo[4,5-c]quinoline (4.0 g, 10.82 mmol) as a brown oil which was used without further purification.
Part C
Using the general method of Example 11 Part F, 2-hexyl-l-[5-(methylthio)pentyl]-1H-imidazo[4,5-c]quinoline (4.0 g, 10.82 mmol) was oxidized to 2-hexyl-l-[5-(methylsulfonyl)pentyl]-1H-imidazo[4,5-c]quinoline-5N-oxide (4.52 g, 10.82 mmol) which was isolated as a tan solid and used without further purification.
Part D
Using the general method of Example 3 Part B 2-hexyl-l-[5-(methylsulfonyl)pentyl]-1H-imidazo[4,5-c]quinoline-5N-oxide (4.0 g, 10.82 mmol) was aminated to provide 2-hexyl-l-[5-(methylsulfonyl)pentyl]-1H-imidazo[4,5-c]quinolin-4-amine. The material was recrystallized from acetonitrile to afford the title compound (2.25 g, 5.40 mmol) as off-white needles, m.p. 168-171 C.
Analysis. Calculated for C22H32N402S: %C 63.43; %H, 7.74; %N, 13.45. Found: %C
63.06; %H, 7.66; %N, 13.81 'H-NMR (300 MHz, DMSO) 6 8.01 (d, J = 8.3 Hz, 1H), 8 7.62 (d, J = 8.3 Hz, 1H), 6 7.42 (t, J = 8.3 Hz, 1H), 6 7.26 (t, J = 8.3 Hz, 1H), 8 6.51 (bs, 2H), 6 4.51 (t, J
= 7.3 Hz, 2H), 8 3.10 (t, J = 7.8 Hz, 2H), 6 2.93 (s, 3H), 6 2.93 (t, J = 7.3 Hz, 2H), 6 1.71-1.87 (m, 6H), 8 1.54 (m, 2H), 6 1.44 (m, 2H), 6 1.33 (m, 4H), 6 0.89 (t, J = 7.3 Hz, 3H) MS (CI) for C22H32N402S mlz 417 (MH+), 337 Example 16 2-(2-methoxyethyl)-1-[5-(methylsulfonyl)pentyl]-1 H-imi dazo [4, 5 -c] quinolin-4-amine NHa N

e is Part A
A round bottom flask was charged with a magnetic stir bar,1V4-[5-(methylthio)pentyl]quinoline-3,4-diamine (3.56 g, 12.93 mmol) and anhydrous pyridine (52 mL) under a nitrogen atmosphere. The resulting homogeneous solution was cooled to 0 C in an ice-water bath. To the cooled solution was added neat 3-methoxypropionyl chloride (2.74 g, 22.36 mmol). After addition of the acid chloride, the reaction was heated to reflux for 14 hours at which time the acylated intermediate was completely consumed.
The solution was cooled and then partitioned between chloroform and saturated aqueous ammonium chloride. The layers were separated. The organic layer was washed with saturated aqueous sodium bicarbonate, dried over anhydrous sodium sulfate, filtered and then concentrated under reduced pressure to afford 2-(2-methoxyethyl)-1-[5-(methylthio)pentyl]-1H-imidazo[4,5-c]quinoline (3.0 g, 8.73 mmol) which was isolated as a brown oil and used without further purification.
Part B
Using the general method of Example 11 Part F, 2-(2-methoxyethyl)-1-[5-(methylthio)pentyl]-1H-imidazo[4,5-c]quinoline (3.0 g, 8.73 mmol) was oxidized to 2-(2-methoxyethyl)-1-[5-(methylsulfonyl)pentyl]-1H-imidazo[4,5-c]quinoline-5N-oxide (3.41 g, 8.73 mmol) which was isolated as a tan solid and used without further purification.
Part C
Using the general method of Example 3 Part B, 2-(2-methoxyethyl)- 1 -[5-(methylsulfonyl)pentyl]-1H-imidazo[4,5-c]quinoline-5N-oxide (3.41 g, 8.73 mmol) was aminated to provide 2-(2-methoxyethyl)-1-[5-(methylsulfonyl)pentyl]-1H-imidazo[4,5-c]quinolin-4-amine. The resulting solid was purified by chromatography over silica gel (95/5 dichloromethane/methanol) to provide a gummy solid. The solid was recrystallized from acetonitrile to give the title compound (0.54 g, 1.38 mmol) as an off-white powder, m.p. 158-160 C.
Analysis. Calculated for C19H26N403S: %C 58.44; %H, 6.71; %N, 14.35. Found: %C
58.24; %H, 6.76; %N, 14.70 'H-NMR (300 MHz, DMSO) 6 8.02 (d, J = 8.3 Hz, 1H), 6 7.62 (d, J = 8.3 Hz, 1H), 6 7.42 (t, J = 8.3 Hz, 1H), 8 7.26 (t, J = 8.3 Hz, 1H), 8 6.50 (bs, 2H), 6 4.53 (t, J
= 7.6 Hz, 2H), 6 3.83(t,J=6.8Hz,2H),63.30(s,3H),53.19(t,J=6.8Hz,2H),53.11 (t, J= 7.8 Hz, 2H), 6 2.93 (s, 3H), 6 1.85 (m, 2H), 8 1.76 (m, 2H), 6 1.57 (m, 2H) MS (CI) for C19H26N403S m/z 391 (MH+), 359 Example 17 2-butyl-l -[5-(methylthio)pentyl]-1H-imidazo[4,5-c]quinolin-4-amine N N
N
Part A
Using the general method of Example 1 Part C, N-(5-chloropentyl)-3-nitroquinolin-4-amine (2.0 g, 6.80 mmol) was reduced to provide A4-(5-chloropentyl)quinoline-3,4-diamine (1.79 g, 6.80 mmol) which was isolated as a brown oil and used without further purification.
Part B
Using the general method of Example 1 Part D, A4-(5-chloropentyl)quinoline-3,4-diamine (1.79 g, 6.80 mmol) was cyclized to 2-butyl-l-(5-chloropentyl)-1H-imidazo[4,5-c]quinoline using trimethyl orthovalerate (2.55 g, 15.72 mmol) and pyridine hydrochloride (0.079 g). The product (1.95 g, 5.91 mmol) was isolated as an off-white solid and used without further purification.

Part C
Using the general method of Example 1 Part E, 2-butyl-l-(5-chloropentyl)-1H-imidazo[4,5-c]quinoline (1.95 g, 5.91 mmol) was oxidized to 2-butyl-l-(5-chloropentyl)-1H-imidazo[4,5-c]quinoline-5N-oxide (2.04 g, 5.91 mmol) which was isolated as a tan solid and used without further purification.
Part D
Using the general method of Example 3 Part B, 2-butyl-l-(5-chloropentyl)-lH-imidazo[4,5-c]quinoline-5N-oxide (2.04 g, 5.91 mmol) was aminated to provide 2-butyl-1-(5-chloropentyl)-1H-imidazo[4,5-c]quinolin-4-amine. The resulting solid was recrystallized from ethanol to afford the product (0.85 g, 2.46 mmol) as a fine white powder, m.p. 144-146 C.
Analysis. Calculated for CI9H25C1N4: %C 66.17; %H, 7.31; %N, 16.24. Found: %C
66.44; %H, 7.55; %N, 16.29 MS (CI) for C19H25C1N4 m/z 345 (MH), 309 Part E
Using the general method of Example 6 Part B, except that the reaction temperature was lowered to 80 C, 2-butyl-l-(5-chloropentyl)-1H-imidazo[4,5-c]quinolin-4-amine (2.0 g, 5.80 mmol) was converted to 2-butyl-l-[5-(methylthio)pentyl]-imidazo[4,5-c]quinolin-4-amine using sodium thiomethoxide (0.68 g, 8.70 mmol) in lieu of sodium benzenethiolate. The resulting solid was partitioned between chloroform and saturated aqueous sodium bicarbonate. The layers were separated. The organic layer was washed with brine, dried over anhydrous sodium sulfate, filtered and then concentrated under reduced pressure to afford a white solid. The material was recrystallized from acetonitrile to give the title compound (1.91 g, 5.36 mmol) as a fine white solid, m.p. 112-114 C.

Analysis. Calculated for C20H28N4S: %C 67.38; %H, 7.92; %N, 15.71. Found: %C
67.26;
%H, 8.08; %N, 15.74 'H-NMR (300 MHz, DMSO) S 8.01 (d, J = 8.3 Hz, 1H), 6 7.61 (d, J = 8.3 Hz, 1H), 8 7.41 (t, J = 8.3 Hz, 1H), S 7.25 (t, J = 8.3 Hz, 1H), S 6.45 (bs, 2H), S 4.50 (t, J
= 7.8 Hz, 2H), S
2.92 (t, J = 7.6 Hz, 2H), 6 2.46 (t, J = 7.3 Hz, 2H), S 2.01 (s, 3H), 6 1.80 (in, 4H), 6 1.42-1.61 (m, 6H), S 0.96 (t, J = 7.3 Hz, 3H) MS (CI) for C20H28N4S m/z 357 (MH+), 309 Example 18 2-butyl-l -[5-(methylsulfinyl)pentyl]-1H-imidazo[4,5-c]quinolin-4-amine NHZ
N N
I
~~ N
6S ,O
A round bottom flask was charged with a magnetic stir bar, 2-butyl-l-[5-(methylthio)pentyl]-1H-imidazo[4,5-c]quinolin-4-amine (1.0 g, 2.80 mmol) and chloroform (14 mL). Solid 3-chloroperbenzoic acid (0.69 g, 3.09 mmol) was added portion wise over 5 minutes and the reaction was stirred at ambient temperature for 20 minutes at which time the starting material was completely consumed. The solution was partitioned between chloroform and saturated aqueous sodium bicarbonate. The layers were separated. The organic layer was washed with saturated aqueous sodium bicarbonate and brine, dried over anhydrous sodium sulfate, filtered and then concentrated under reduced pressure to afford an off-white solid which was shown by 1H-NMR to be the 3-chlorobenzoic acid salt of the desired product. The solid was stirred in water and then made basic (pH 10) by addition of solid sodium carbonate. The resulting free base was collected by filtration to provide a white solid which was recrystallized from acetonitrile to give 2-butyl-l-[5-(methylsulfinyl)pentyl]-lH-imidazo[4,5-c]quinolin-4-amine (0.40 g, 1.07 mmol) as a white powder, m.p. 119-121 C.
Analysis. Calculated for C20H28N40S (H20)1: %C 61.51; %H, 7.74; %N, 14.35.
Found:
%C 61.64; %H, 7.82; %N, 14.32 'H-NMR (300 MHz, DMSO) 8 8.01 (d, J = 8.3 Hz, 1H), 8 7.60 (d, J = 8.3 Hz, 1H), 6 7.41 (t, J = 8.3 Hz, 1H), 8 7.26 (t, J = 8.3 Hz, 1H), 6 6.44 (bs, 2H), 6 4.51 (t, J
= 7.6 Hz, 2H), 6 2.92 (t, J = 7.8 Hz, 2H), 6 2.57-2.74 (m, 2H), 6 2.50 (s, 3H), 8 1.80 (m, 4H), 6 1.66 (m, 2H),61.55(m,2H),51.48(m,2H),50.96(t,J=7.3Hz,3H) MS (CI) for C2oH28N40S (H20)1 m/z 373 (MH+), 309, 253 Example 19 2-butyl- l -[3 -(methylsulfonyl)propyl] -1 H-imidazo [4, 5-c] quinolin-4-amine NHZ
N N
N
,0 ,S~

Part A
A round bottom flask was charged with a magnetic stir bar, 3-[(3-nitroquinolin-yl)amino]propan-1-ol (20.75 g, 83.93 mmol), thionyl chloride (15.0 g, 125.89 mmol), and dichloromethane (420 mL). The bright yellow, homogeneous solution was stirred at ambient temperature for 2 hours at which time the starting material was completely consumed. The volatiles were removed under reduced pressure and the resulting solid stirred in water (400 mL) made basic (pH 10) with solid sodium carbonate. A
bright yellow solid was collected by filtration to afford N-(3-chloropropyl)-3-nitroquinolin-4-amine (21.63 g, 81.41 mmol) which was used without further purification.
Part B
Using the general method of Example 1 Part C, N-(3-chloropropyl)-3-nitroquinolin-4-amine (10.0 g, 37.63 mmol) was reduced to provide N4-(3-chloropropyl)quinoline-3,4-diamine (8.87 g, 37.63 mmol) which was isolated as a brown oil and used without further purification.
Part C

Using the general method of Example 1 Part D, N4-(3-chloropropyl)quinoline-3,4-diamine (8.87 g, 37.63 mmol) was cyclized to provide 2-butyl-l-(3-chloropropyl)-1H-imidazo[4,5-c]quinoline using trimethyl orthovalerate (7.33 g, 45.16 mmol) and pyridine hydrochloride (0.43 g). The resulting solid was triturated with ethyl ether and collected by filtration to afford the product (9.00 g, 29.82 mmol) as an off-white solid.
The material was used without further purification.

Part D
Using the general method of Example 1 Part E, 2 butyl-l-(3-chloropropyl)-1H-imidazo[4,5-c]quinoline (9.0 g, 29.82 mmol) was oxidized to 2-butyl-l-(3-chloropropyl)-1H-imidazo[4,5-c]quinoline-5N-oxide (9.48 g, 29.82 mmol) which was isolated as a tan solid and used without purification.
Part E
Using the general method of Example 3 Part B, 2-butyl-l-(3-chloropropyl)-1H-imidazo[4,5-c]quinoline-5N-oxide (9.48 g, 29.82 mmol) was aminated to provide 2-butyl-1-(3-chloropropyl)-1H-imidazo[4,5-c]quinolin-4-amine. The resulting solid was purified by chromatography over silica gel (95/5 dichloromethane/methanol) to provide the product (6.4 g, 20.20 mmol) as a tan solid.
Part F
Using the general method of Example 6 Part B, except that the reaction temperature was lowered to 80 C, 2-butyl-l-(3-chloropropyl)-1H-imidazo[4,5-c]quinolin-4-amine (2.0 g, 6.31 mmol) was converted to 2-butyl-l-[3-(methylthio)propyl]-lH-imidazo[4,5-c]quinolin-4-amine using sodium thiomethoxide (0.74 g, 9.47 mmol) in lieu of sodium benzenethiolate. The resulting solid was partitioned between chloroform and saturated aqueous sodium bicarbonate. The layers were separated. The organic layer was washed with brine, dried over anhydrous sodium sulfate, filtered and then concentrated under reduced pressure to afford the title compound (2.0 g, 6.09 mmol) as a white solid.
The material was used without further purification.
Part G
Using the general method of Example 5 Part A, 2-butyl-1-[3-(methylthio)propyl]-1H-imidazo[4,5-c]quinolin-4-amine (2.0 g, 6.09 mmol) was oxidized to 2-butyl-l-[3-(methylsulfonyl)propyl]-1H-imidazo[4,5-c]quinolin-4-amine. The resulting solid was triturated with methanol and collected by filtration to afford the title compound (0.96 g, 2.66 mmol) as an off-white powder, m.p. 233-236 C.
Analysis. Calculated for C18H24N402S: %C 59.98; %H, 6.71; %N, 15.54. Found: %C
59.71; %H, 6.65; %N, 15.43 1H-NMR (300 MHz, DMSO) 8 8.10 (d, J = 8.3 Hz, 1H), 6 7.61 (d, J = 8.3 Hz, 1H), 6 7.42 (t, J = 8.3 Hz, 1H), 8 7.25 (t, J = 8.3 Hz, 1H), S 6.47 (bs, 2H), 6 4.66 (t, J
= 7.8 Hz, 2H), 6 3.40 (t, J = 7.3 Hz, 2H), 6 3.01 (s, 3H), 6 2.94 (t, J = 7.8 Hz, 2H), S 2.22 (m, 2H), 6 1.80 (m, 2H), 6 1.46 (sextet, J = 7.3 Hz, 2H), 8 0.96 (t, J = 7.3 Hz, 3H) MS (CI) for C18H24N402S m/z 361 (MH+), 281, 235 Example 20 2-butyl-l-[3-(phenylsulfonyl)propyl]-1H-imidazo[4,5-c]quinolin-4-amine N N
N
O

O
Part A
A round bottom flask was charged with a magnetic stir bar, benzenethiol (0.68 g, 6.21 mmol), sodium hydride (0.25 g, 60% dispersion, 6.21 mmol), and anhydrous dimethyl formamide (28 mL) under a nitrogen atmosphere. After the reaction mixture had stirred at ambient temperature for 30 minutes, 2-butyl- 1 -(3 -chloropropyl)-1 H-imidazo [4,5 -c]quinolin-4-amine (1.64 g, 5.18 mmol) was added and the resulting cloudy solution was heated to 80 C and maintained at 80 C for 2.5 hours at which time the starting material was completely consumed. The hot solution was poured into rapidly stirred water (200 mL). The resulting mixture was extracted with chloroform (2x). The combined organic layers were washed with saturated aqueous sodium bicarbonate and brine, dried over anhydrous sodium sulfate, filtered and then concentrated under reduced pressure to afford a light yellow oil. The material was purified by chromatography over silica gel (95/5 dichloromnethane/methanol) to provide 2-butyl-l-[3-(phenylthio)propyl]-lH-imidazo[4,5-c]quinolin-4-amine (1.38 g, 3.53 mmol) as a white solid.
Part B
Using the general method of Example 5 Part A, 2-butyl- 1 - [3 -(phenylthio)propyl] -1H-imidazo[4,5-c]quinolin-4-amine (1.38 g, 3.53 mmol) was oxidized to 2-butyl-l-[3-(phenylsulfonyl)propyl]-1H-imidazo[4,5-c]quinolin-4-amine. The resulting solid was recrystallized from ethanol to provide the title compound (0.85 g, 2.01 mmol) as an off-white powder, m.p. 224-227 C.

Analysis. Calculated for C23H26N402S: %C 65.38; %H, 6.20; %N, 13.26. Found: %C
65.25; %H, 6.23; %N, 13.20 'H-NMR (300 MHz, DMSO) 6 7.96 (d, J = 8.3 Hz, 1H), 6 7.89 (m, 2H), 6 7.73 (m, 1H), 6 7.63 (m, 3H), 6 7.40 (t, J = 8.3 Hz, 1H), 6 7.17 (t, J = 8.3 Hz, 1H), 6 6.46 (bs, 2H), 6 4.60 (t, J = 7.8 Hz, 2H), 6 3.66 (t, J = 7.3 Hz, 2H), 6 2.86 (t, J = 7.8 Hz, 211), 6 2.04 (m, 2H), 6 1.73 (p, J = 7.6 Hz, 2H), 6 1.39 (sextet, J = 7.3 Hz, 2H), 6 0.92 (t, J = 7.3 Hz, 3H) MS (CI) for C23H26N402S m/z 423 (MH+), 322, 281 CYTOKINE INDUCTION IN HUMAN CELLS
An in vitro human blood cell system is used to assess cytokine induction.
Activity is based on the measurement of interferon and tumor necrosis factor (a) (IFN
and TNF, respectively) secreted into culture media as described by Testerman et. al. In "Cytokine Induction by the Immunomodulators Imiquimod and S-27609", Journal of Leukocyte Biology, 58, 365-372 (September, 1995).
Blood Cell Preparation for Culture Whole blood from healthy human donors is collected by venipuncture into EDTA
vacutainer tubes. Peripheral blood mononuclear cells (PBMCs) are separated from whole blood by density gradient centrifugation using Histopaque -1077. The PBMCs are washed twice with Hank's Balanced Salts Solution and then are suspended at 3-4 x 106 cells/mL in RPMI complete. The PBMC suspension is added to 48 well flat bottom sterile tissue culture plates (Costar, Cambridge, MA or Becton Dickinson Labware, Lincoln Park, NJ) containing an equal volume of RPMI complete media containing test compound.
Compound Preparation The compounds are solubilized in dimethyl sulfoxide (DMSO). The DMSO
concentration should not exceed a final concentration of 1 % for addition to the culture wells. The compounds are generally tested initially at concentrations ranging from 0.12 to M. Compounds showing activity at 0.12 M may then be tested at lower concentrations.
Incubation 30 The solution of test compound is added at 60 gM to the first well containing RPMI
complete and serial 3 fold dilutions are made in the wells. The PBMC
suspension is then added to the wells in an equal volume, bringing the test compound concentrations to the desired range (0.12 to 30 M). The final concentration of PBMC suspension is 1.5-2 X
106 cells/mL. The plates are covered with sterile plastic lids, mixed gently and then incubated for 18 to 24 hours at 37 C in a 5% carbon dioxide atmosphere.
Separation Following incubation the plates are centrifuged for 5-10 minutes at 1000 rpm (-200 x g) at 4 C. The cell-free culture supernatant is removed with a sterile polypropylene pipet and transferred to sterile polypropylene tubes. Samples are maintained at -30 to -70 C until analysis. The samples are analyzed for interferon (a) and for tumor necrosis factor (a) by ELISA
Interferon (a) and Tumor Necrosis Factor (a) Analysis by ELISA
Interferon (a) concentration is determined by ELISA using a Human Multi-Species kit from PBL Biomedical Laboratories, New Brunswick, NJ. Results are expressed in pg/mL.
Tumor necrosis factor (a) (TNF)concentration is determined using ELISA kits available from Genzyme, Cambridge, MA; R&D Systems, Minneapolis, MN; or Pharmingen, San Diego, CA. Results are expressed in pg/mL.

The table below lists the lowest concentration found to induce interferon and the lowest concentration found to induce tumor necrosis factor for each compound.
A "*"
indicates that no induction was seen at any of the tested concentrations (0.12, 0.37, 1.11, 3.33, 10 and 30 M).

Cytokine Induction in Human Cells Example Lowest Effective Concentration ( M) Number Interferon Tumor Necrosis Factor 1 0.12 0.12 2 0.12 0.37 3 0.04 0.12 4 0.01 0.01 5 0.01 0.04 6 3.33 10 Cytokine Induction in Human Cells Example Lowest Effective Concentration ( M) Number Interferon Tumor Necrosis Factor 7 3.33 10 9 3.33 3.33 1.11 1.11 11 0.01 0.12 12 0.12 10 13 0.12 3.33 14 3.33 10 0.04 *
16 0.01 0.04 17 0.01 0.04 18 0.01 0.12 19 0.04 0.37 0.04 0.37

Claims (25)

1 A compound of the formula (I):

wherein: X is -CHR3-, -CHR3-alkyl-, or -CHR3-alkenyl-;
Z is -S-, -SO-, or -SO2-;
R1 is: -alkyl;
-aryl;
-heteroaryl;
-heterocyclyl;
-alkenyl;
-R4-aryl;
-R4-heteroaryl; or -R4-heterocyclyl;
R2 is: -hydrogen;
-alkyl;
-alkenyl;
-aryl;
-heteroaryl;
-heterocyclyl;
-alkyl-Y-alkyl;
- alkyl-Y- alkenyl;

-alkyl-Y-aryl; or - alkyl or alkenyl substituted by one or more substituents being:
-OH;
-halogen;
-N(R3)2;
-CO-N(R3)2;
-CO-C1-10 alkyl;
-CO-O-C1-10 alkyl;
-N3;
-aryl;
-heteroaryl;
-heterocyclyl;
-CO-aryl; or -CO-heteroaryl;
each R3 is independently H or C1-10 alkyl;
each R4 is independently alkyl or alkenyl;
each Y is independently -O- or -S(O)0-2-;
n is 0 to 4; and each R present is independently C1-10 alkyl, C1-10 alkoxy, hydroxy, halogen or trifluoromethyl;
or a pharmaceutically acceptable salt thereof.
2. A compound of claim 1, wherein Z is -S-.
3. A compound of claim 1, wherein Z is -SO2-.
4. A compound of claim 1, wherein R1 is -alkyl.
5. A compound of claim 1, wherein R1 is -aryl.
6. A compound of claim 1, wherein R1 is phenyl.
7. A compound of claim 1, wherein R1 is heteroaryl.
8. A compound of claim 1, wherein X is -(CH2)2-6-.
9. A compound of claim 1, wherein R2 is H.
10. A compound of claim 1, wherein R2 is -alkyl-O-alkyl.
11. A compound of claim 1, wherein R2 is -alkyl.
12. A compound being:
2-butyl-1-[4-(phenylthio)butyl]-1H-imidazo[4,5-c]quinolin-4-amine;
2-butyl-1-[2-(phenylthio)ethyl]-6,7,8,9-tetrahydro-1H-imidazo[4,5-c]quinolin-4-amine;
2-butyl-1-[4-(phenylsulfonyl)butyl]-1H-imidazo[4,5-c]quinolin-4-amine;
2-butyl-1-[4-(methylthio)butyl]-1H-imidazo[4,5-c]quinolin-4-amine;
2-butyl-1-[4-(methylsulfonyl)butyl]-1H-imidazo[4,5-c]quinolin-4-amine;
1-[2-(phenylthio)ethyl]-1H-imidazo[4,5-c]quinolin-4-amine;
1-[4-(phenyl sulfonyl)butyl]-1H-imidazo[4,5-c]quinolin-4-amine;
1-[4-(methylsulfonyl)butyl]-1H-imidazo[4,5-c]quinolin-4-amine;
1-[4-(phenylthio)butyl]-1H-imidazo[4,5-c]quinolin-4-amine;
1-[4-(methylthio)butyl]-1H-imidazo[4,5-c]quinolin-4-amine;
2-butyl-1-[5-(methylsulfonyl)pentyl]-1H-imidazo[4,5-c]quinolin-4-amine;
2-methyl-1-[5-(methylsulfonyl)pentyl]-1H-imidazo[4,5-c]quinolin-4-amine;
2-ethyl-1-[5-(methylsulfonyl)pentyl]-1H-imidazo[4,5-c]quinolin-4-amine;
1-[5-(methylsulfonyl)pentyl]-1H-imidazo[4,5-c]quinolin-4-amine;
2-hexyl-1-[5-(methylsulfonyl)pentyl]-1H-imidazo[4,5-c]quinolin-4-amine;
2-(2-methoxyethyl)-1-[5-(methylsulfonyl)pentyl]-1H-imidazo[4,5-c]quinolin-4-amine;

2-butyl-1-[5-(methylthio)pentyl]-1H-imidazo[4,5-c]quinolin-4-amine;
2-butyl-1-[5-(methylsulfinyl)pentyl]-1H-imidazo[4,5-c]quinolin-4-amine;
2-butyl-1-[3-(methylsulfonyl)propyl]-1H-imidazo[4,5-c]quinolin-4-amine; or 2-butyl-1-[3-(phenylsulfonyl)propyl]-1H-imidazo [4,5-c] quinolin-4-amine;
or a pharmaceutically acceptable salt thereof.
13. A compound of the formula (II):
wherein: X is -CHR3-, -CHR3-alkyl-, or -CHR3-alkenyl-;
Z is -S-, -SO-, or -SO2-;
R1 is: -alkyl;
-aryl;
-heteroaryl;
-heterocyclyl;
-alkenyl;
-R4-aryl;
-R4- heteroaryl; or -R4-heterocyclyl;
R2 is: -hydrogen;
-alkyl;
-alkenyl;
-aryl;
-heteroaryl;

-heterocyclyl;
-alkyl-Y-alkyl;
-alkyl-Y-alkenyl;
-alkyl-Y-aryl; or - alkyl or alkenyl substituted by one or more substituents being:
-OH;
-halogen;
-N(R3)2;
-CO-N(R3)2;
-CO-C1-10 alkyl;
-CO-O-C1-10 alkyl;
-N3;
-aryl;
-heteroaryl;
-heterocyclyl;
-CO-aryl; or -CO-heteroaryl;
each R3 is independently H or C1-10 alkyl;
each R4 is independently alkyl or alkenyl;
each Y is independently -O- or -S(O)0-2-;
n is 0 to 4; and each R present is independently C1-10 alkyl, C1-10 alkoxy, hydroxy, halogen or trifluoromethyl;
or a pharmaceutically acceptable salt thereof.
14. A compound of claim 13, wherein R1 is phenyl.
15. A compound of claim 13, wherein R2 is H or alkyl.
16. A compound of claim 13, wherein R2 is -alkyl-O-alkyl.
17. A pharmaceutical composition comprising a compound or a pharmaceutically acceptable salt thereof as defined in any one of claims 1 to 16, and a pharmaceutically acceptable carrier.
18. Use of a therapeutically effective amount of a compound as defined in any one of claims 1 to 16, for inducing cytokine biosynthesis in an animal.
19. The use of claim 18, wherein the cytokine is IFN-.alpha..
20. Use of a therapeutically effective amount of a compound as defined in any one of claims 1 to 16, for treating a viral disease in an animal.
21. Use of therapeutically effective amount of a compound as defined in any one of claims 1 to 16, for treating neoplastic disease in an animal.
22. Use of a therapeutically effective amount of a compound as defined in any one of claims 1 to 16, for the manufacture of a medicament for inducing cytokine biosynthesis in an animal.
23. The use of claim 22, wherein the cytokine is IFN-.alpha..
24. Use of a therapeutically effective amount of a compound as defined in any one of claims 1 to 16, for the manufacture of a medicament for treating a viral disease in an animal.
25. Use of a therapeutically effective amount of a compound as defined in any one of claims 1 to 16, for the manufacture of a medicament for treating a neoplastic disease in an animal.
CA2436846A 2000-12-08 2001-12-06 Thioether substituted imidazoquinolines Expired - Fee Related CA2436846C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US25421800P 2000-12-08 2000-12-08
US60/254,218 2000-12-08
PCT/US2001/046697 WO2002046192A2 (en) 2000-12-08 2001-12-06 Thioether substituted imidazoquinolines

Publications (2)

Publication Number Publication Date
CA2436846A1 CA2436846A1 (en) 2002-06-13
CA2436846C true CA2436846C (en) 2010-11-16

Family

ID=22963391

Family Applications (6)

Application Number Title Priority Date Filing Date
CA2436980A Expired - Fee Related CA2436980C (en) 2000-12-08 2001-12-06 Amido ether substituted imidazoquinolines
CA002430844A Withdrawn CA2430844A1 (en) 2000-12-08 2001-12-06 Aryl ether substituted imidazoquinolines
CA2436846A Expired - Fee Related CA2436846C (en) 2000-12-08 2001-12-06 Thioether substituted imidazoquinolines
CA002436984A Abandoned CA2436984A1 (en) 2000-12-08 2001-12-06 Urea substituted imidazoquinoline ethers
CA002431151A Withdrawn CA2431151A1 (en) 2000-12-08 2001-12-06 Heterocyclic ether substituted imidazoquinolines
CA002436983A Abandoned CA2436983A1 (en) 2000-12-08 2001-12-06 Sulfonamido ether substituted imidazoquinolines

Family Applications Before (2)

Application Number Title Priority Date Filing Date
CA2436980A Expired - Fee Related CA2436980C (en) 2000-12-08 2001-12-06 Amido ether substituted imidazoquinolines
CA002430844A Withdrawn CA2430844A1 (en) 2000-12-08 2001-12-06 Aryl ether substituted imidazoquinolines

Family Applications After (3)

Application Number Title Priority Date Filing Date
CA002436984A Abandoned CA2436984A1 (en) 2000-12-08 2001-12-06 Urea substituted imidazoquinoline ethers
CA002431151A Withdrawn CA2431151A1 (en) 2000-12-08 2001-12-06 Heterocyclic ether substituted imidazoquinolines
CA002436983A Abandoned CA2436983A1 (en) 2000-12-08 2001-12-06 Sulfonamido ether substituted imidazoquinolines

Country Status (31)

Country Link
US (8) US6656938B2 (en)
EP (6) EP1341790B1 (en)
JP (7) JP4437189B2 (en)
KR (6) KR20030070049A (en)
CN (6) CN1297554C (en)
AR (6) AR035668A1 (en)
AT (3) ATE319711T1 (en)
AU (12) AU2002239517B2 (en)
BR (6) BR0116032A (en)
CA (6) CA2436980C (en)
CZ (6) CZ295848B6 (en)
DE (3) DE60126645T2 (en)
DK (3) DK1341790T3 (en)
EE (6) EE200300271A (en)
ES (3) ES2242782T3 (en)
HK (3) HK1064383A1 (en)
HR (6) HRP20030466A2 (en)
HU (6) HUP0400710A2 (en)
IL (6) IL155884A0 (en)
MX (6) MXPA03004974A (en)
NO (6) NO20032449D0 (en)
NZ (6) NZ526086A (en)
PL (7) PL365995A1 (en)
PT (2) PT1341791E (en)
RU (6) RU2302418C2 (en)
SI (1) SI1341790T1 (en)
SK (6) SK7122003A3 (en)
TW (3) TW584633B (en)
UA (2) UA75622C2 (en)
WO (6) WO2002046193A2 (en)
ZA (6) ZA200305271B (en)

Families Citing this family (206)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5741908A (en) 1996-06-21 1998-04-21 Minnesota Mining And Manufacturing Company Process for reparing imidazoquinolinamines
UA67760C2 (en) * 1997-12-11 2004-07-15 Міннесота Майнінг Енд Мануфакчурінг Компані Imidazonaphthyridines and use thereof to induce the biosynthesis of cytokines
US6756382B2 (en) 1999-06-10 2004-06-29 3M Innovative Properties Company Amide substituted imidazoquinolines
US6331539B1 (en) 1999-06-10 2001-12-18 3M Innovative Properties Company Sulfonamide and sulfamide substituted imidazoquinolines
US6541485B1 (en) 1999-06-10 2003-04-01 3M Innovative Properties Company Urea substituted imidazoquinolines
US6573273B1 (en) * 1999-06-10 2003-06-03 3M Innovative Properties Company Urea substituted imidazoquinolines
US6916925B1 (en) 1999-11-05 2005-07-12 3M Innovative Properties Co. Dye labeled imidazoquinoline compounds
JP3436512B2 (en) * 1999-12-28 2003-08-11 株式会社デンソー Accelerator device
US6664265B2 (en) 2000-12-08 2003-12-16 3M Innovative Properties Company Amido ether substituted imidazoquinolines
US6545017B1 (en) * 2000-12-08 2003-04-08 3M Innovative Properties Company Urea substituted imidazopyridines
UA75622C2 (en) 2000-12-08 2006-05-15 3M Innovative Properties Co Aryl ether substituted imidazoquinolines, pharmaceutical composition based thereon
US6667312B2 (en) 2000-12-08 2003-12-23 3M Innovative Properties Company Thioether substituted imidazoquinolines
US6677348B2 (en) 2000-12-08 2004-01-13 3M Innovative Properties Company Aryl ether substituted imidazoquinolines
US6525064B1 (en) 2000-12-08 2003-02-25 3M Innovative Properties Company Sulfonamido substituted imidazopyridines
US6660735B2 (en) 2000-12-08 2003-12-09 3M Innovative Properties Company Urea substituted imidazoquinoline ethers
US6545016B1 (en) 2000-12-08 2003-04-08 3M Innovative Properties Company Amide substituted imidazopyridines
US6664264B2 (en) * 2000-12-08 2003-12-16 3M Innovative Properties Company Thioether substituted imidazoquinolines
US6677347B2 (en) * 2000-12-08 2004-01-13 3M Innovative Properties Company Sulfonamido ether substituted imidazoquinolines
US6660747B2 (en) * 2000-12-08 2003-12-09 3M Innovative Properties Company Amido ether substituted imidazoquinolines
US7226928B2 (en) * 2001-06-15 2007-06-05 3M Innovative Properties Company Methods for the treatment of periodontal disease
EP1450804B9 (en) * 2001-11-29 2009-04-01 3M Innovative Properties Company Pharmaceutical formulations comprising an immune response modifier
CA2365732A1 (en) 2001-12-20 2003-06-20 Ibm Canada Limited-Ibm Canada Limitee Testing measurements
US6677349B1 (en) 2001-12-21 2004-01-13 3M Innovative Properties Company Sulfonamide and sulfamide substituted imidazoquinolines
IL147953A (en) * 2002-02-01 2008-04-13 Meir Bialer Derivatives and pharmaceutical compositions of n-hydroxymethyl tetramethylcyclopropyl-
PT1478327E (en) 2002-02-22 2015-08-04 Meda Ab Method of reducing and treating uvb-induced immunosuppression
GB0211649D0 (en) * 2002-05-21 2002-07-03 Novartis Ag Organic compounds
CN1674894A (en) * 2002-06-07 2005-09-28 3M创新有限公司 Ether substituted imidazopyridines
US7718651B2 (en) 2002-07-02 2010-05-18 Southern Research Institute Inhibitors of FtsZ and uses thereof
DK1545597T3 (en) * 2002-08-15 2011-01-31 3M Innovative Properties Co Immune Stimulating Compositions and Methods for Stimulating an Immune Response
JP2006503068A (en) 2002-09-26 2006-01-26 スリーエム イノベイティブ プロパティズ カンパニー 1H-Imidazo dimer
JP2006513212A (en) * 2002-12-20 2006-04-20 スリーエム イノベイティブ プロパティズ カンパニー Aryl / hetaryl substituted imidazoquinolines
EP2572714A1 (en) 2002-12-30 2013-03-27 3M Innovative Properties Company Immunostimulatory Combinations
EP1592302A4 (en) * 2003-02-13 2007-04-25 3M Innovative Properties Co Methods and compositions related to irm compounds and toll-like receptor 8
WO2004075865A2 (en) * 2003-02-27 2004-09-10 3M Innovative Properties Company Selective modulation of tlr-mediated biological activity
EP1601365A4 (en) 2003-03-04 2009-11-11 3M Innovative Properties Co Prophylactic treatment of uv-induced epidermal neoplasia
JP2006519877A (en) * 2003-03-07 2006-08-31 スリーエム イノベイティブ プロパティズ カンパニー 1-amino 1H-imidazoquinoline
US7163947B2 (en) * 2003-03-07 2007-01-16 3M Innovative Properties Company 1-Amino 1H-imidazoquinolines
ATE556711T1 (en) 2003-03-13 2012-05-15 3M Innovative Properties Co METHOD FOR IMPROVING SKIN QUALITY
WO2004080292A2 (en) 2003-03-13 2004-09-23 3M Innovative Properties Company Method of tattoo removal
JP2006523212A (en) * 2003-03-13 2006-10-12 スリーエム イノベイティブ プロパティズ カンパニー Diagnosis method of skin lesion
US20040192585A1 (en) 2003-03-25 2004-09-30 3M Innovative Properties Company Treatment for basal cell carcinoma
EP1617871A4 (en) * 2003-04-10 2010-10-06 3M Innovative Properties Co Delivery of immune response modifier compounds using metal-containing particulate support materials
US20040265351A1 (en) 2003-04-10 2004-12-30 Miller Richard L. Methods and compositions for enhancing immune response
EP1617845A4 (en) * 2003-04-28 2006-09-20 3M Innovative Properties Co Compositions and methods for induction of opioid receptors
WO2004110991A2 (en) * 2003-06-06 2004-12-23 3M Innovative Properties Company PROCESS FOR IMIDAZO[4,5-c]PYRIDIN-4-AMINES
US20050032829A1 (en) * 2003-06-06 2005-02-10 3M Innovative Properties Company Process for imidazo[4,5-c]pyridin-4-amines
CA2534313C (en) * 2003-08-05 2013-03-19 3M Innovative Properties Company Formulations containing an immune response modifier
JP2007502288A (en) * 2003-08-12 2007-02-08 スリーエム イノベイティブ プロパティズ カンパニー Oxime-substituted imidazo-containing compounds
EP2939693A1 (en) 2003-08-14 2015-11-04 3M Innovative Properties Company Lipid-modified immune response modifiers
ES2545826T3 (en) * 2003-08-14 2015-09-16 3M Innovative Properties Company Lipid Modified Immune Response Modifiers
WO2005020912A2 (en) 2003-08-25 2005-03-10 3M Innovative Properties Company Delivery of immune response modifier compounds
WO2005018574A2 (en) * 2003-08-25 2005-03-03 3M Innovative Properties Company Immunostimulatory combinations and treatments
AU2004268625B2 (en) 2003-08-27 2011-03-31 3M Innovative Properties Company Aryloxy and arylalkyleneoxy substituted imidazoquinolines
EP1663222A4 (en) * 2003-09-02 2008-05-21 3M Innovative Properties Co Methods related to the treatment of mucosal associated conditions
JP2007504269A (en) 2003-09-05 2007-03-01 スリーエム イノベイティブ プロパティズ カンパニー Method for treating CD5 + B cell lymphoma
EP1664342A4 (en) * 2003-09-17 2007-12-26 3M Innovative Properties Co Selective modulation of tlr gene expression
KR20060120069A (en) 2003-10-03 2006-11-24 쓰리엠 이노베이티브 프로퍼티즈 컴파니 Pyrazolopyridines and analogs thereof
US7544697B2 (en) 2003-10-03 2009-06-09 Coley Pharmaceutical Group, Inc. Pyrazolopyridines and analogs thereof
US20090075980A1 (en) * 2003-10-03 2009-03-19 Coley Pharmaceutical Group, Inc. Pyrazolopyridines and Analogs Thereof
ES2544477T3 (en) * 2003-10-03 2015-08-31 3M Innovative Properties Company Alkoxy substituted imidazoquinolines
WO2005041891A2 (en) * 2003-10-31 2005-05-12 3M Innovative Properties Company Neutrophil activation by immune response modifier compounds
EP1682544A4 (en) * 2003-11-14 2009-05-06 3M Innovative Properties Co Hydroxylamine substituted imidazo ring compounds
CA2545774A1 (en) * 2003-11-14 2005-06-02 3M Innovative Properties Company Oxime substituted imidazo ring compounds
KR20060117329A (en) * 2003-11-21 2006-11-16 노파르티스 아게 1h-imidazoquinoline derivatives as protein kinase inhibitors
AR046845A1 (en) * 2003-11-21 2005-12-28 Novartis Ag DERIVATIVES OF 1H-IMIDAZO [4,5-C] QUINOLINE FOR THE TREATMENT OF PROTEIN-KINASE DEPENDENT DISEASES
NZ547467A (en) 2003-11-25 2010-06-25 3M Innovative Properties Co Substituted imidazo ring system and methods
AU2004293096A1 (en) * 2003-11-25 2005-06-09 3M Innovative Properties Company Hydroxylamine and oxime substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines
WO2005055932A2 (en) * 2003-12-02 2005-06-23 3M Innovative Properties Company Therapeutic combinations and methods including irm compounds
AU2004315771A1 (en) * 2003-12-04 2005-08-25 3M Innovative Properties Company Sulfone substituted imidazo ring ethers
JP2007517035A (en) 2003-12-29 2007-06-28 スリーエム イノベイティブ プロパティズ カンパニー Arylalkenyl and arylalkynyl substituted imidazoquinolines
AU2004312510A1 (en) * 2003-12-29 2005-07-21 3M Innovative Properties Company Piperazine, [1,4]diazepane, [1,4]diazocane, and [1,5]diazocane fused imidazo ring compounds
US20050158325A1 (en) * 2003-12-30 2005-07-21 3M Innovative Properties Company Immunomodulatory combinations
EP1699398A4 (en) * 2003-12-30 2007-10-17 3M Innovative Properties Co Enhancement of immune responses
EP1699788A2 (en) * 2003-12-30 2006-09-13 3M Innovative Properties Company Imidazoquinolinyl, imidazopyridinyl and imidazonaphthyridinyl sulfonamides
ES2665342T3 (en) * 2004-03-15 2018-04-25 Meda Ab Formulations and methods for immune response modifiers
US8697873B2 (en) * 2004-03-24 2014-04-15 3M Innovative Properties Company Amide substituted imidazopyridines, imidazoquinolines, and imidazonaphthyridines
US20070166384A1 (en) * 2004-04-09 2007-07-19 Zarraga Isidro Angelo E Methods , composition and preparations for delivery of immune response modifiers
US20050267145A1 (en) * 2004-05-28 2005-12-01 Merrill Bryon A Treatment for lung cancer
WO2005123079A2 (en) * 2004-06-14 2005-12-29 3M Innovative Properties Company Urea substituted imidazopyridines, imidazoquinolines, and imidazonaphthyridines
WO2005123080A2 (en) 2004-06-15 2005-12-29 3M Innovative Properties Company Nitrogen-containing heterocyclyl substituted imidazoquinolines and imidazonaphthyridines
US8026366B2 (en) * 2004-06-18 2011-09-27 3M Innovative Properties Company Aryloxy and arylalkyleneoxy substituted thiazoloquinolines and thiazolonaphthyridines
WO2006028545A2 (en) * 2004-06-18 2006-03-16 3M Innovative Properties Company Substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines
WO2006009832A1 (en) * 2004-06-18 2006-01-26 3M Innovative Properties Company Substituted imidazo ring systems and methods
US8541438B2 (en) 2004-06-18 2013-09-24 3M Innovative Properties Company Substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines
WO2006065280A2 (en) 2004-06-18 2006-06-22 3M Innovative Properties Company Isoxazole, dihydroisoxazole, and oxadiazole substituted imidazo ring compounds and methods
WO2006038923A2 (en) 2004-06-18 2006-04-13 3M Innovative Properties Company Aryl substituted imidazonaphthyridines
PL1789042T3 (en) * 2004-09-02 2012-09-28 3M Innovative Properties Co 1-alkoxy 1h-imidazo ring systems and methods
AU2005282523A1 (en) 2004-09-02 2006-03-16 3M Innovative Properties Company 2-amino 1H imidazo ring systems and methods
WO2006026760A2 (en) * 2004-09-02 2006-03-09 3M Innovative Properties Company 1-amino imidazo-containing compounds and methods
US20080193468A1 (en) * 2004-09-08 2008-08-14 Children's Medical Center Corporation Method for Stimulating the Immune Response of Newborns
MX2007003078A (en) * 2004-09-14 2007-05-16 Novartis Vaccines & Diagnostic Imidazoquinoline compounds.
US20070243215A1 (en) * 2004-10-08 2007-10-18 Miller Richard L Adjuvant for Dna Vaccines
WO2006063072A2 (en) * 2004-12-08 2006-06-15 3M Innovative Properties Company Immunomodulatory compositions, combinations and methods
US8080560B2 (en) * 2004-12-17 2011-12-20 3M Innovative Properties Company Immune response modifier formulations containing oleic acid and methods
WO2006071997A2 (en) 2004-12-30 2006-07-06 3M Innovative Properties Company Treatment for cutaneous metastases
US8436176B2 (en) * 2004-12-30 2013-05-07 Medicis Pharmaceutical Corporation Process for preparing 2-methyl-1-(2-methylpropyl)-1H-imidazo[4,5-c][1,5]naphthyridin-4-amine
US8034938B2 (en) 2004-12-30 2011-10-11 3M Innovative Properties Company Substituted chiral fused [1,2]imidazo[4,5-c] ring compounds
KR20070107685A (en) * 2004-12-30 2007-11-07 다케다 야쿠힌 고교 가부시키가이샤 1-(2-methylpropyl)-1h-imidazo[4,5-c][1,5]naphthyridin-4-amine ethanesulfonate and 1-(2-methylpropyl)-1h-imidazo[4,5-c][1,5]naphthyridin-4-amine methanesulfonate
ES2392647T3 (en) * 2004-12-30 2012-12-12 3M Innovative Properties Company Chiral tetracyclic compounds that induce interferon biosynthesis
WO2006084251A2 (en) 2005-02-04 2006-08-10 Coley Pharmaceutical Group, Inc. Aqueous gel formulations containing immune reponse modifiers
ES2475728T3 (en) 2005-02-09 2014-07-11 3M Innovative Properties Company Thiazoloquinolines and alkoxy substituted thiazolonaphthyridines
EP1877056A2 (en) 2005-02-09 2008-01-16 Coley Pharmaceutical Group, Inc. Oxime and hydroxylamine substituted thiazoloý4,5-c¨ring compounds and methods
US7968563B2 (en) 2005-02-11 2011-06-28 3M Innovative Properties Company Oxime and hydroxylamine substituted imidazo[4,5-c] ring compounds and methods
JP2008532933A (en) * 2005-02-11 2008-08-21 コーリー ファーマシューティカル グループ,インコーポレイテッド Substituted imidazoquinolines and substituted imidazonaphthyridines
PL2351772T3 (en) 2005-02-18 2017-01-31 Glaxosmithkline Biologicals Sa Proteins and nucleic acids from meningitis/sepsis-associated Escherichia coli
US8062644B2 (en) 2005-02-18 2011-11-22 Novartis Vaccines & Diagnostics Srl. Immunogens from uropathogenic Escherichia coli
JP2008531568A (en) 2005-02-23 2008-08-14 コーリー ファーマシューティカル グループ,インコーポレイテッド Imidazonaphthyridine substituted with hydroxyalkyl
EP1850849A2 (en) * 2005-02-23 2007-11-07 Coley Pharmaceutical Group, Inc. Method of preferentially inducing the biosynthesis of interferon
AU2006223634A1 (en) * 2005-02-23 2006-09-21 Coley Pharmaceutical Group, Inc. Hydroxyalkyl substituted imidazoquinolines
AU2006216798A1 (en) * 2005-02-23 2006-08-31 Coley Pharmaceutical Group, Inc. Hydroxyalkyl substituted imidazoquinoline compounds and methods
JP2008533148A (en) 2005-03-14 2008-08-21 スリーエム イノベイティブ プロパティズ カンパニー Treatment method for actinic keratosis
AU2006232375A1 (en) 2005-04-01 2006-10-12 Coley Pharmaceutical Group, Inc. 1-substituted pyrazolo (3,4-c) ring compounds as modulators of cytokine biosynthesis for the treatment of viral infections and neoplastic diseases
EP1869043A2 (en) 2005-04-01 2007-12-26 Coley Pharmaceutical Group, Inc. Pyrazolopyridine-1,4-diamines and analogs thereof
US20080193474A1 (en) * 2005-04-25 2008-08-14 Griesgraber George W Immunostimulatory Compositions
EP2614709A1 (en) 2005-07-18 2013-07-17 Novartis AG Small animal model for HCV replication
ZA200803029B (en) 2005-09-09 2009-02-25 Coley Pharm Group Inc Amide and carbamate derivatives of alkyl substituted /V-[4-(4-amino-1H-imidazo[4,5-c] quinolin-1-yl)butyl] methane-sulfonamides and methods
US8476292B2 (en) * 2005-09-09 2013-07-02 3M Innovative Properties Company Amide and carbamate derivatives of N-{2-[4-amino-2-(ethoxymethyl)-1H-imidazo[4,5-c] quinolin-1-Yl]-1,1-dimethylethyl}methanesulfonamide and methods
US8889154B2 (en) 2005-09-15 2014-11-18 Medicis Pharmaceutical Corporation Packaging for 1-(2-methylpropyl)-1H-imidazo[4,5-c] quinolin-4-amine-containing formulation
AU2006310339B2 (en) 2005-11-04 2013-01-10 Novartis Ag Influenza vaccines including combinations of particulate adjuvants and immunopotentiators
PT2368572T (en) 2005-11-04 2020-06-16 Seqirus Uk Ltd Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
US8088790B2 (en) * 2005-11-04 2012-01-03 3M Innovative Properties Company Hydroxy and alkoxy substituted 1H-imidazoquinolines and methods
CN102755645A (en) 2005-11-04 2012-10-31 诺华疫苗和诊断有限公司 Influenza vaccines with reduced amount of emulsion adjuvant
EP1951302A2 (en) 2005-11-04 2008-08-06 Novartis Vaccines and Diagnostics S.r.l. Influenza vaccine with reduced amount of oil-in-water emulsion as adjuvant
WO2007085969A2 (en) 2006-01-27 2007-08-02 Novartis Vaccines And Diagnostics Gmbh & Co Kg Influenza vaccines containing hemagglutinin and matrix proteins
EP1988896A4 (en) 2006-02-22 2011-07-27 3M Innovative Properties Co Immune response modifier conjugates
US8329721B2 (en) 2006-03-15 2012-12-11 3M Innovative Properties Company Hydroxy and alkoxy substituted 1H-imidazonaphthyridines and methods
EP2357184B1 (en) 2006-03-23 2015-02-25 Novartis AG Imidazoquinoxaline compounds as immunomodulators
ES2388556T3 (en) * 2006-03-23 2012-10-16 Novartis Ag Immunopotentiating compounds
CA2647100A1 (en) * 2006-03-23 2007-09-27 Novartis Ag Methods for the preparation of imidazole-containing compounds
CA2646349A1 (en) 2006-03-24 2007-10-04 Novartis Vaccines And Diagnostics Gmbh & Co Kg Storage of influenza vaccines without refrigeration
WO2007126825A2 (en) 2006-03-31 2007-11-08 Novartis Ag Combined mucosal and parenteral immunization against hiv
ATE522541T1 (en) 2006-06-09 2011-09-15 Novartis Ag BACTERIAL ADHESIN CONFORMERS
WO2008008432A2 (en) 2006-07-12 2008-01-17 Coley Pharmaceutical Group, Inc. Substituted chiral fused( 1,2) imidazo (4,5-c) ring compounds and methods
GB0614460D0 (en) 2006-07-20 2006-08-30 Novartis Ag Vaccines
EP2586790A3 (en) 2006-08-16 2013-08-14 Novartis AG Immunogens from uropathogenic Escherichia coli
WO2008030511A2 (en) * 2006-09-06 2008-03-13 Coley Pharmaceuticial Group, Inc. Substituted 3,4,6,7-tetrahydro-5h, 1,2a,4a,8-tetraazacyclopenta[cd]phenalenes
ES2536401T3 (en) 2006-09-11 2015-05-25 Novartis Ag Making vaccines against influenza viruses without using eggs
EP2679240A1 (en) 2006-12-06 2014-01-01 Novartis AG Vaccines including antigen from four strains of influenza virus
US20080149123A1 (en) 2006-12-22 2008-06-26 Mckay William D Particulate material dispensing hairbrush with combination bristles
GB0700562D0 (en) 2007-01-11 2007-02-21 Novartis Vaccines & Diagnostic Modified Saccharides
WO2009001217A2 (en) 2007-06-27 2008-12-31 Novartis Ag Low-additive influenza vaccines
GB0714963D0 (en) 2007-08-01 2007-09-12 Novartis Ag Compositions comprising antigens
GB0810305D0 (en) 2008-06-05 2008-07-09 Novartis Ag Influenza vaccination
GB0818453D0 (en) 2008-10-08 2008-11-12 Novartis Ag Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
CN101909624A (en) * 2008-01-15 2010-12-08 麦达股份公司 Treatment of colon diseases or prevention of colorectal carcinoma with imidazoquinoline derivatives
KR101208778B1 (en) 2008-03-03 2012-12-05 노파르티스 아게 Compounds and compositions as tlr activity modulators
EP3459563A1 (en) 2008-03-18 2019-03-27 Seqirus UK Limited Improvements in preparation of influenza virus vaccine antigens
EP2403526B1 (en) 2009-03-06 2019-05-15 GlaxoSmithKline Biologicals SA Chlamydia antigens
CN102439153B (en) 2009-03-25 2015-07-22 德克萨斯大学系统董事会 Compositions for stimulation of mammalian innate immune resistance to pathogens
MX363222B (en) 2009-04-14 2019-03-15 Novartis Ag Compositions for immunising against staphylococcus aerus.
USH2283H1 (en) 2009-04-27 2013-09-03 Novartis Ag Vaccines for protecting against influenza
AU2013203591B2 (en) * 2009-05-01 2017-01-19 University Court Of The University Of Dundee Treatment or prophylaxis of proliferative conditions
GB0907551D0 (en) 2009-05-01 2009-06-10 Univ Dundee Treatment or prophylaxis of proliferative conditions
TW201116294A (en) 2009-07-15 2011-05-16 Novartis Ag RSV F protein compositions and methods for making same
PT2464658E (en) 2009-07-16 2015-01-14 Novartis Ag Detoxified escherichia coli immunogens
GB0918392D0 (en) 2009-10-20 2009-12-02 Novartis Ag Diagnostic and therapeutic methods
GB0919690D0 (en) 2009-11-10 2009-12-23 Guy S And St Thomas S Nhs Foun compositions for immunising against staphylococcus aureus
GB201009861D0 (en) 2010-06-11 2010-07-21 Novartis Ag OMV vaccines
DK2606047T3 (en) 2010-08-17 2017-03-27 3M Innovative Properties Co COMPOSITIONS AND FORMULATIONS WITH LIPIDIZED IMMUNE RESPONSE-MODIFIING COMPOUND AND PROCEDURES THEREOF
CN103370317B (en) 2010-12-16 2015-10-07 阿斯利康(瑞典)有限公司 Can be used for imidazo [4, the 5-c] quinoline-1-radical derivative for the treatment of
US10342862B2 (en) 2011-01-26 2019-07-09 Glaxosmithkline Biologicals, Sa RSV immunization regimen
LT3275892T (en) 2011-05-13 2020-04-10 Glaxosmithkline Biologicals S.A. Pre-fusion rsv f antigens
US8728486B2 (en) 2011-05-18 2014-05-20 University Of Kansas Toll-like receptor-7 and -8 modulatory 1H imidazoquinoline derived compounds
MX355623B (en) 2011-06-03 2018-04-25 3M Innovative Properties Co Hydrazino 1h-imidazoquinolin-4-amines and conjugates made therefrom.
US9475804B2 (en) 2011-06-03 2016-10-25 3M Innovative Properties Company Heterobifunctional linkers with polyethylene glycol segments and immune response modifier conjugates made therefrom
US20130023736A1 (en) 2011-07-21 2013-01-24 Stanley Dale Harpstead Systems for drug delivery and monitoring
WO2013068949A1 (en) 2011-11-07 2013-05-16 Novartis Ag Carrier molecule comprising a spr0096 and a spr2021 antigen
WO2013108272A2 (en) 2012-01-20 2013-07-25 International Centre For Genetic Engineering And Biotechnology Blood stage malaria vaccine
CN103566377A (en) 2012-07-18 2014-02-12 上海博笛生物科技有限公司 Targeted immunotherapy for cancer
AU2014203896B2 (en) 2013-01-07 2018-05-31 The Trustees Of The University Of Pennsylvania Compositions and methods for treating cutaneous T cell lymphoma
EP3632458A1 (en) 2013-07-26 2020-04-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of bacterial infections
JP6446054B2 (en) 2013-11-05 2018-12-26 スリーエム・イノベイティブ・プロパティーズ・カンパニー Sesame oil-based injection formulation
EP2870974A1 (en) 2013-11-08 2015-05-13 Novartis AG Salmonella conjugate vaccines
SG11201605449YA (en) 2014-01-10 2016-08-30 Birdie Biopharmaceuticals Inc Compounds and compositions for immunotherapy
SI3122378T1 (en) 2014-03-26 2020-03-31 Glaxosmithkline Biologicals S.A. Mutant staphylococcal antigens
CN112546231A (en) * 2014-07-09 2021-03-26 博笛生物科技有限公司 Combination therapeutic compositions and combination therapeutic methods for treating cancer
JP6760919B2 (en) 2014-07-09 2020-09-23 バーディー バイオファーマシューティカルズ インコーポレイテッド Anti-PD-L1 combination for treating tumors
CN105461767B (en) * 2014-08-07 2019-03-12 富力 A kind of chemical synthesis process of forsythin
CN112587672A (en) 2014-09-01 2021-04-02 博笛生物科技有限公司 anti-PD-L1 conjugates for the treatment of tumors
WO2016044839A2 (en) 2014-09-19 2016-03-24 The Board Of Regents Of The University Of Texas System Compositions and methods for treating viral infections through stimulated innate immunity in combination with antiviral compounds
MX2018003215A (en) * 2015-09-14 2018-06-08 Pfizer Novel imidazo [4,5-c] quinoline and imidazo [4,5-c][1,5] naphthyridine derivatives as lrrk2 inhibitors.
CN108770357B (en) * 2015-09-29 2022-10-28 芝加哥大学 Polymer conjugate vaccines
WO2017059280A1 (en) 2015-10-02 2017-04-06 The University Of North Carolina At Chapel Hill Novel pan-tam inhibitors and mer/axl dual inhibitors
CN115252792A (en) 2016-01-07 2022-11-01 博笛生物科技有限公司 anti-EGFR combinations for the treatment of tumors
CN115350279A (en) 2016-01-07 2022-11-18 博笛生物科技有限公司 anti-HER 2 combinations for the treatment of tumors
CN115554406A (en) 2016-01-07 2023-01-03 博笛生物科技有限公司 anti-CD 20 combinations for the treatment of tumors
CN110234401B (en) 2016-11-09 2024-03-01 德克萨斯大学系统董事会 Methods and compositions for adaptive immunomodulation
CN108794467A (en) 2017-04-27 2018-11-13 博笛生物科技有限公司 2- amino-quinoline derivatives
JP7080501B2 (en) 2017-06-23 2022-06-06 バーディー バイオファーマシューティカルズ インコーポレイテッド Pharmaceutical composition
CN111511740B (en) 2017-12-20 2023-05-16 3M创新有限公司 Amide substituted imidazo [4,5-C ] quinoline compounds with branched linking groups for use as immune response modifiers
SG11202007386RA (en) 2018-02-02 2020-08-28 Steven Albert Everett Small molecule drug conjugates of gemcitabine monophosphate
US11370788B2 (en) * 2018-02-28 2022-06-28 3M Innovative Properties Company Substituted imidazo[4,5-c]quinoline compounds with an N-1 branched group
CA3034912A1 (en) 2018-02-28 2019-08-28 Pfizer Inc. Il-15 variants and uses thereof
US11434292B2 (en) 2018-05-23 2022-09-06 Pfizer Inc. Antibodies specific for CD3 and uses thereof
MX2020012607A (en) 2018-05-23 2021-01-29 Pfizer Antibodies specific for gucy2c and uses thereof.
CA3101277A1 (en) 2018-05-24 2019-11-28 3M Innovative Properties Company N-1 branched cycloalkyl substituted imidazo[4,5-c]quinoline compounds, compositions, and methods
WO2020023680A1 (en) * 2018-07-24 2020-01-30 Torque Therapeutics, Inc. Tlr7/8 agonists and liposome compositions
US20210323962A1 (en) * 2018-11-26 2021-10-21 3M Innovative Properties Company N-1 branched alkyl ether substituted imidazo[4,5-c]quinoline compounds, compositions, and methods
US20220370606A1 (en) 2018-12-21 2022-11-24 Pfizer Inc. Combination Treatments Of Cancer Comprising A TLR Agonist
WO2020163118A1 (en) * 2019-02-07 2020-08-13 Canwell Biotech Limited Phosphorus imidazoquinoline amine derivatives, pharmaceutical compositions and therapeutic methods thereof
US20220226488A1 (en) 2019-02-12 2022-07-21 Ambrx, Inc. Compositions containing, methods and uses of antibody-tlr agonist conjugates
BR112022008039A2 (en) * 2019-10-29 2022-07-12 Prime Reach Trading Ltd 4-AMINO-IMIDAZOQUINOLINE COMPOUNDS AND RELATED USES
WO2021116420A1 (en) 2019-12-13 2021-06-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of tlr7 and/or tlr8 agonists for the treatment of leptospirosis
BR112022009723A2 (en) 2019-12-17 2022-08-09 Pfizer SPECIFIC ANTIBODIES TO CD47, PD-L1, AND USES THEREOF
CN116323668A (en) 2020-07-17 2023-06-23 辉瑞公司 Therapeutic antibodies and uses thereof
CA3190606A1 (en) 2020-08-20 2022-02-24 Ambrx, Inc. Antibody-tlr agonist conjugates, methods and uses thereof

Family Cites Families (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2135210A (en) * 1937-03-13 1938-11-01 John R Farrar Golf ball
US3314941A (en) 1964-06-23 1967-04-18 American Cyanamid Co Novel substituted pyridodiazepins
US3692907A (en) * 1970-10-27 1972-09-19 Richardson Merrell Inc Treating viral infections with bis-basic ethers and thioethers of fluorenone and fluorene and pharmaceutical compositons of the same
US3819190A (en) * 1972-10-02 1974-06-25 D Nepela Golf ball
US4284276A (en) * 1980-02-13 1981-08-18 Worst Joseph C Grooved golf ball
ZA848968B (en) 1983-11-18 1986-06-25 Riker Laboratories Inc 1h-imidazo(4,5-c)quinolines and 1h-imidazo(4,5-c)quinolin-4-amines
IL73534A (en) * 1983-11-18 1990-12-23 Riker Laboratories Inc 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds
US4880779A (en) * 1987-07-31 1989-11-14 Research Corporation Technologies, Inc. Method of prevention or treatment of AIDS by inhibition of human immunodeficiency virus
US5238944A (en) 1988-12-15 1993-08-24 Riker Laboratories, Inc. Topical formulations and transdermal delivery systems containing 1-isobutyl-1H-imidazo[4,5-c]quinolin-4-amine
US5756747A (en) 1989-02-27 1998-05-26 Riker Laboratories, Inc. 1H-imidazo 4,5-c!quinolin-4-amines
US5037986A (en) 1989-03-23 1991-08-06 Minnesota Mining And Manufacturing Company Olefinic 1H-imidazo[4,5-c]quinolin-4-amines
US4929624A (en) 1989-03-23 1990-05-29 Minnesota Mining And Manufacturing Company Olefinic 1H-imidazo(4,5-c)quinolin-4-amines
NZ232740A (en) 1989-04-20 1992-06-25 Riker Laboratories Inc Solution for parenteral administration comprising a 1h-imidazo(4,5-c) quinolin-4-amine derivative, an acid and a tonicity adjuster
US4988815A (en) * 1989-10-26 1991-01-29 Riker Laboratories, Inc. 3-Amino or 3-nitro quinoline compounds which are intermediates in preparing 1H-imidazo[4,5-c]quinolines
US5054153A (en) * 1989-12-01 1991-10-08 Silliman Paul D Golf club cleaner
ES2071340T3 (en) * 1990-10-05 1995-06-16 Minnesota Mining & Mfg PROCEDURE FOR THE PREPARATION OF IMIDAZO (4,5-C) QUINOLIN-4-AMINAS.
US5175296A (en) * 1991-03-01 1992-12-29 Minnesota Mining And Manufacturing Company Imidazo[4,5-c]quinolin-4-amines and processes for their preparation
US5389640A (en) 1991-03-01 1995-02-14 Minnesota Mining And Manufacturing Company 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines
EP0582581B1 (en) * 1991-03-01 1999-05-06 Minnesota Mining And Manufacturing Company 1-SUBSTITUTED, 2-SUBSTITUTED 1H-IMIDAZO[4,5-c]QUINOLIN-4-AMINES
US5268376A (en) 1991-09-04 1993-12-07 Minnesota Mining And Manufacturing Company 1-substituted 1H-imidazo[4,5-c]quinolin-4-amines
US5266575A (en) * 1991-11-06 1993-11-30 Minnesota Mining And Manufacturing Company 2-ethyl 1H-imidazo[4,5-ciquinolin-4-amines
IL105325A (en) 1992-04-16 1996-11-14 Minnesota Mining & Mfg Immunogen/vaccine adjuvant composition
FR2692159B1 (en) * 1992-06-10 1996-10-11 Vartan Berberian BALL FOR BALL GAMES AND METHODS OF OBTAINING SUCH A BALL.
US5395937A (en) * 1993-01-29 1995-03-07 Minnesota Mining And Manufacturing Company Process for preparing quinoline amines
CA2167042A1 (en) 1993-07-15 1995-01-26 Kyle J. Lindstrom Imidazo[4,5-c]pyridin-4-amines
US5648516A (en) 1994-07-20 1997-07-15 Minnesota Mining And Manufacturing Company Fused cycloalkylimidazopyridines
US5352784A (en) * 1993-07-15 1994-10-04 Minnesota Mining And Manufacturing Company Fused cycloalkylimidazopyridines
US5644063A (en) 1994-09-08 1997-07-01 Minnesota Mining And Manufacturing Company Imidazo[4,5-c]pyridin-4-amine intermediates
US5482936A (en) 1995-01-12 1996-01-09 Minnesota Mining And Manufacturing Company Imidazo[4,5-C]quinoline amines
JPH09116911A (en) * 1995-10-20 1997-05-02 Canon Inc Image pickup system
JPH09208584A (en) 1996-01-29 1997-08-12 Terumo Corp Amide derivative, pharmaceutical preparation containing the same, and intermediate for synthesizing the same
JPH09255926A (en) 1996-03-26 1997-09-30 Diatex Co Ltd Pressure-sensitive tape
US5741908A (en) * 1996-06-21 1998-04-21 Minnesota Mining And Manufacturing Company Process for reparing imidazoquinolinamines
US5693811A (en) * 1996-06-21 1997-12-02 Minnesota Mining And Manufacturing Company Process for preparing tetrahdroimidazoquinolinamines
US5759109A (en) * 1996-09-09 1998-06-02 Martini; Byron Rocco Simulated golf ball instructional device
ATE367159T1 (en) * 1996-10-25 2007-08-15 Minnesota Mining & Mfg COMPOUNDS THAT ALTER THE IMMUNE RESPONSE FOR THE TREATMENT OF TH2-MEDIATED AND RELATED DISEASES
US5939090A (en) 1996-12-03 1999-08-17 3M Innovative Properties Company Gel formulations for topical drug delivery
JP4101302B2 (en) * 1997-01-09 2008-06-18 テルモ株式会社 Novel amide derivatives and synthetic intermediates
UA67760C2 (en) * 1997-12-11 2004-07-15 Міннесота Майнінг Енд Мануфакчурінг Компані Imidazonaphthyridines and use thereof to induce the biosynthesis of cytokines
JPH11222432A (en) 1998-02-03 1999-08-17 Terumo Corp Preparation for external use containing amide derivative inducing interferon
JPH11255926A (en) 1998-03-13 1999-09-21 Toray Ind Inc Silicone molding and its production
US6239965B1 (en) * 1998-05-22 2001-05-29 Matsushita Electric Industrial Co., Ltd. Electrolytic capacitor and method of producing the same
US6110929A (en) 1998-07-28 2000-08-29 3M Innovative Properties Company Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof
JP2000119271A (en) * 1998-08-12 2000-04-25 Hokuriku Seiyaku Co Ltd 1h-imidazopyridine derivative
EP1140091B1 (en) * 1999-01-08 2005-09-21 3M Innovative Properties Company Formulations comprising imiquimod or other immune response modifiers for treating cervical dysplasia
US20020058674A1 (en) 1999-01-08 2002-05-16 Hedenstrom John C. Systems and methods for treating a mucosal surface
US6558951B1 (en) * 1999-02-11 2003-05-06 3M Innovative Properties Company Maturation of dendritic cells with immune response modifying compounds
JP2000247884A (en) 1999-03-01 2000-09-12 Sumitomo Pharmaceut Co Ltd Arachidonic acid-induced skin disease-treating agent
US6451810B1 (en) * 1999-06-10 2002-09-17 3M Innovative Properties Company Amide substituted imidazoquinolines
US6573273B1 (en) * 1999-06-10 2003-06-03 3M Innovative Properties Company Urea substituted imidazoquinolines
US6756382B2 (en) 1999-06-10 2004-06-29 3M Innovative Properties Company Amide substituted imidazoquinolines
US6331539B1 (en) 1999-06-10 2001-12-18 3M Innovative Properties Company Sulfonamide and sulfamide substituted imidazoquinolines
US6541485B1 (en) * 1999-06-10 2003-04-01 3M Innovative Properties Company Urea substituted imidazoquinolines
US6376669B1 (en) * 1999-11-05 2002-04-23 3M Innovative Properties Company Dye labeled imidazoquinoline compounds
US6894060B2 (en) 2000-03-30 2005-05-17 3M Innovative Properties Company Method for the treatment of dermal lesions caused by envenomation
US20020055517A1 (en) * 2000-09-15 2002-05-09 3M Innovative Properties Company Methods for delaying recurrence of herpes virus symptoms
JP2002145777A (en) 2000-11-06 2002-05-22 Sumitomo Pharmaceut Co Ltd Therapeutic agent for arachidonic acid-induced dermatosis
US6664265B2 (en) * 2000-12-08 2003-12-16 3M Innovative Properties Company Amido ether substituted imidazoquinolines
US6545017B1 (en) * 2000-12-08 2003-04-08 3M Innovative Properties Company Urea substituted imidazopyridines
US6525064B1 (en) 2000-12-08 2003-02-25 3M Innovative Properties Company Sulfonamido substituted imidazopyridines
US6660747B2 (en) 2000-12-08 2003-12-09 3M Innovative Properties Company Amido ether substituted imidazoquinolines
US6660735B2 (en) 2000-12-08 2003-12-09 3M Innovative Properties Company Urea substituted imidazoquinoline ethers
UA75622C2 (en) 2000-12-08 2006-05-15 3M Innovative Properties Co Aryl ether substituted imidazoquinolines, pharmaceutical composition based thereon
US6677347B2 (en) * 2000-12-08 2004-01-13 3M Innovative Properties Company Sulfonamido ether substituted imidazoquinolines
US6545016B1 (en) * 2000-12-08 2003-04-08 3M Innovative Properties Company Amide substituted imidazopyridines
US6664264B2 (en) 2000-12-08 2003-12-16 3M Innovative Properties Company Thioether substituted imidazoquinolines
US20020110840A1 (en) 2000-12-08 2002-08-15 3M Innovative Properties Company Screening method for identifying compounds that selectively induce interferon alpha
US6664260B2 (en) 2000-12-08 2003-12-16 3M Innovative Properties Company Heterocyclic ether substituted imidazoquinolines
UA74593C2 (en) 2000-12-08 2006-01-16 3M Innovative Properties Co Substituted imidazopyridines
US6667312B2 (en) * 2000-12-08 2003-12-23 3M Innovative Properties Company Thioether substituted imidazoquinolines
US6677348B2 (en) 2000-12-08 2004-01-13 3M Innovative Properties Company Aryl ether substituted imidazoquinolines
CN1523987A (en) 2001-06-15 2004-08-25 3M创新有限公司 Immune response modifiers for the treatment of periodontal disease
WO2003020889A2 (en) 2001-08-30 2003-03-13 3M Innovative Properties Company Methods of maturing plasmacytoid dendritic cells using immune response modifier molecules
WO2003094836A2 (en) 2001-10-12 2003-11-20 University Of Iowa Research Foundation Methods and products for enhancing immune responses using imidazoquinoline compounds
US20040014779A1 (en) 2001-11-16 2004-01-22 3M Innovative Properties Company Methods and compositions related to IRM compounds and toll-like recptor pathways
EP1450804B9 (en) 2001-11-29 2009-04-01 3M Innovative Properties Company Pharmaceutical formulations comprising an immune response modifier
US6677349B1 (en) 2001-12-21 2004-01-13 3M Innovative Properties Company Sulfonamide and sulfamide substituted imidazoquinolines
PT1478327E (en) 2002-02-22 2015-08-04 Meda Ab Method of reducing and treating uvb-induced immunosuppression
GB0211649D0 (en) 2002-05-21 2002-07-03 Novartis Ag Organic compounds
AU2003233519A1 (en) 2002-05-29 2003-12-19 3M Innovative Properties Company Process for imidazo(4,5-c)pyridin-4-amines
CN1674894A (en) 2002-06-07 2005-09-28 3M创新有限公司 Ether substituted imidazopyridines
DK1545597T3 (en) 2002-08-15 2011-01-31 3M Innovative Properties Co Immune Stimulating Compositions and Methods for Stimulating an Immune Response
JP2006503068A (en) 2002-09-26 2006-01-26 スリーエム イノベイティブ プロパティズ カンパニー 1H-Imidazo dimer
WO2004053057A2 (en) 2002-12-11 2004-06-24 3M Innovative Properties Company Gene expression systems and recombinant cell lines
AU2003287316A1 (en) 2002-12-11 2004-06-30 3M Innovative Properties Company Assays relating to toll-like receptor activity
JP2006513212A (en) * 2002-12-20 2006-04-20 スリーエム イノベイティブ プロパティズ カンパニー Aryl / hetaryl substituted imidazoquinolines
EP2572714A1 (en) 2002-12-30 2013-03-27 3M Innovative Properties Company Immunostimulatory Combinations
EP1592302A4 (en) 2003-02-13 2007-04-25 3M Innovative Properties Co Methods and compositions related to irm compounds and toll-like receptor 8
WO2004075865A2 (en) 2003-02-27 2004-09-10 3M Innovative Properties Company Selective modulation of tlr-mediated biological activity
EP1601365A4 (en) 2003-03-04 2009-11-11 3M Innovative Properties Co Prophylactic treatment of uv-induced epidermal neoplasia
JP2006519877A (en) 2003-03-07 2006-08-31 スリーエム イノベイティブ プロパティズ カンパニー 1-amino 1H-imidazoquinoline
JP2006523212A (en) 2003-03-13 2006-10-12 スリーエム イノベイティブ プロパティズ カンパニー Diagnosis method of skin lesion
WO2004080292A2 (en) 2003-03-13 2004-09-23 3M Innovative Properties Company Method of tattoo removal
ATE556711T1 (en) 2003-03-13 2012-05-15 3M Innovative Properties Co METHOD FOR IMPROVING SKIN QUALITY
US20040192585A1 (en) 2003-03-25 2004-09-30 3M Innovative Properties Company Treatment for basal cell carcinoma
US20040191833A1 (en) 2003-03-25 2004-09-30 3M Innovative Properties Company Selective activation of cellular activities mediated through a common toll-like receptor
EP1617871A4 (en) 2003-04-10 2010-10-06 3M Innovative Properties Co Delivery of immune response modifier compounds using metal-containing particulate support materials
DE602004026891D1 (en) 2003-09-05 2010-06-10 Anadys Pharmaceuticals Inc TLR7 LIGANDS FOR THE TREATMENT OF HEPATITIS C

Also Published As

Publication number Publication date
JP2004521092A (en) 2004-07-15
RU2302418C2 (en) 2007-07-10
PL361948A1 (en) 2004-10-18
PL366115A1 (en) 2005-01-24
NZ526106A (en) 2004-11-26
IL155903A0 (en) 2003-12-23
JP4437189B2 (en) 2010-03-24
CN1511155A (en) 2004-07-07
UA74852C2 (en) 2006-02-15
JP2010031040A (en) 2010-02-12
ATE353895T1 (en) 2007-03-15
US20030212091A1 (en) 2003-11-13
HK1066005A1 (en) 2005-03-11
RU2315049C2 (en) 2008-01-20
EP1343784A2 (en) 2003-09-17
CA2436980A1 (en) 2002-06-13
CA2436846A1 (en) 2002-06-13
WO2002046189A3 (en) 2003-03-20
HRP20030466A2 (en) 2004-06-30
KR20040047733A (en) 2004-06-05
AR035667A1 (en) 2004-06-23
CZ20031563A3 (en) 2004-02-18
AU2002232482B2 (en) 2006-10-19
AU2002232497B2 (en) 2006-11-02
KR20030070049A (en) 2003-08-27
EE200300270A (en) 2003-10-15
ES2242782T3 (en) 2005-11-16
NO20032452L (en) 2003-07-16
AR035665A1 (en) 2004-06-23
DE60117859D1 (en) 2006-05-04
CZ20031591A3 (en) 2003-11-12
SK7102003A3 (en) 2003-10-07
BR0116032A (en) 2006-02-21
PL365883A1 (en) 2005-01-10
EP1341789A2 (en) 2003-09-10
AU2002239530B2 (en) 2006-09-28
US20030158192A1 (en) 2003-08-21
PL207340B1 (en) 2010-12-31
MXPA03004972A (en) 2004-01-29
PT1341791E (en) 2005-09-30
NO20032596L (en) 2003-06-06
DE60117859T2 (en) 2006-11-23
SK7122003A3 (en) 2003-11-04
AU2002230618B2 (en) 2006-11-02
ZA200305270B (en) 2004-08-26
AU3953002A (en) 2002-06-18
SK7112003A3 (en) 2003-12-02
AU2002239516B2 (en) 2006-11-09
HRP20030461A2 (en) 2004-06-30
CA2436983A1 (en) 2002-06-13
AR035669A1 (en) 2004-06-23
CN1297554C (en) 2007-01-31
DK1343784T3 (en) 2006-07-10
HRP20030464A2 (en) 2004-06-30
UA75622C2 (en) 2006-05-15
BR0116464A (en) 2006-02-21
PT1341790E (en) 2007-05-31
BR0116026A (en) 2004-12-21
EP1341790B1 (en) 2007-02-14
WO2002046193A3 (en) 2003-02-27
WO2002046188A3 (en) 2003-03-13
ZA200305271B (en) 2004-10-08
ATE296301T1 (en) 2005-06-15
US6656938B2 (en) 2003-12-02
WO2002046191A2 (en) 2002-06-13
NZ526087A (en) 2004-11-26
DE60111076D1 (en) 2005-06-30
HUP0400704A2 (en) 2004-06-28
AU3951602A (en) 2002-06-18
HK1069166A1 (en) 2005-05-13
PL366330A1 (en) 2005-01-24
TWI293300B (en) 2008-02-11
HK1064383A1 (en) 2005-01-28
CN1479738A (en) 2004-03-03
CN1252070C (en) 2006-04-19
DE60126645T2 (en) 2007-11-22
ES2260323T3 (en) 2006-11-01
MXPA03004975A (en) 2003-09-05
US20020193396A1 (en) 2002-12-19
ZA200305272B (en) 2005-01-26
HUP0400710A2 (en) 2004-06-28
EE200300272A (en) 2003-10-15
IL156043A0 (en) 2003-12-23
NO20032452D0 (en) 2003-05-28
US20040106640A1 (en) 2004-06-03
SK287732B6 (en) 2011-07-06
CZ20031592A3 (en) 2004-01-14
RU2003116123A (en) 2004-11-20
HRP20030463A2 (en) 2004-04-30
CN1479739A (en) 2004-03-03
HUP0600600A2 (en) 2006-11-28
EE200300268A (en) 2003-10-15
NO20032451L (en) 2003-07-16
NO20032449L (en) 2003-05-28
ZA200305274B (en) 2004-10-18
ZA200305273B (en) 2004-10-08
PL392462A1 (en) 2010-11-22
MXPA03004974A (en) 2003-09-05
WO2002046191A3 (en) 2003-03-13
US6670372B2 (en) 2003-12-30
NO326159B1 (en) 2008-10-13
CA2430844A1 (en) 2002-06-13
US20050148619A1 (en) 2005-07-07
AR035664A1 (en) 2004-06-23
US7132429B2 (en) 2006-11-07
NO20032473L (en) 2003-05-30
MXPA03005012A (en) 2003-09-05
NZ526088A (en) 2004-12-24
PL365907A1 (en) 2005-01-10
AU3249702A (en) 2002-06-18
US6953804B2 (en) 2005-10-11
RU2003116649A (en) 2005-02-10
SK7152003A3 (en) 2003-09-11
TW584633B (en) 2004-04-21
US6683088B2 (en) 2004-01-27
CN1894244A (en) 2007-01-10
EP1343784B1 (en) 2006-03-08
NO20032451D0 (en) 2003-05-28
CN1537111A (en) 2004-10-13
RU2308456C2 (en) 2007-10-20
RU2003116063A (en) 2004-12-10
CZ295848B6 (en) 2005-11-16
CZ20031562A3 (en) 2004-03-17
SK287264B6 (en) 2010-04-07
WO2002046190A2 (en) 2002-06-13
CZ20031560A3 (en) 2004-05-12
US7049439B2 (en) 2006-05-23
BR0116047A (en) 2003-09-30
NO20032596D0 (en) 2003-06-06
WO2002046190A3 (en) 2003-07-17
MXPA03004973A (en) 2004-01-29
JP2004523498A (en) 2004-08-05
NZ526086A (en) 2005-11-25
RU2003116059A (en) 2005-02-10
MXPA03005011A (en) 2003-09-05
HRP20030467A2 (en) 2004-04-30
EP1341790A2 (en) 2003-09-10
KR20040028690A (en) 2004-04-03
EE200300271A (en) 2003-10-15
RU2351598C2 (en) 2009-04-10
NO20032449D0 (en) 2003-05-28
AU3248202A (en) 2002-06-18
CZ303462B6 (en) 2012-09-26
EP1341791A2 (en) 2003-09-10
NO20032595D0 (en) 2003-06-06
PL365995A1 (en) 2005-01-24
US20050234088A1 (en) 2005-10-20
HRP20030467B1 (en) 2009-04-30
WO2002046193A2 (en) 2002-06-13
IL155904A0 (en) 2003-12-23
IL155950A0 (en) 2003-12-23
TWI222972B (en) 2004-11-01
EP1341792A2 (en) 2003-09-10
CZ20031561A3 (en) 2004-04-14
SI1341790T1 (en) 2007-06-30
SK6842003A3 (en) 2003-12-02
BR0116052A (en) 2006-02-21
AR035668A1 (en) 2004-06-23
AU3951702A (en) 2002-06-18
CN1247575C (en) 2006-03-29
CN1253452C (en) 2006-04-26
WO2002046192A2 (en) 2002-06-13
KR20040028691A (en) 2004-04-03
ATE319711T1 (en) 2006-03-15
AU3061802A (en) 2002-06-18
BR0116470A (en) 2005-08-16
US20040077678A1 (en) 2004-04-22
DE60111076T2 (en) 2006-05-04
IL156044A0 (en) 2003-12-23
JP2004515501A (en) 2004-05-27
NO20032473D0 (en) 2003-05-30
SK7132003A3 (en) 2003-10-07
KR20030070050A (en) 2003-08-27
CA2436980C (en) 2011-03-29
EE200300275A (en) 2003-10-15
HUP0600605A2 (en) 2006-11-28
HUP0600338A2 (en) 2006-08-28
KR20040023576A (en) 2004-03-18
CN1487939A (en) 2004-04-07
DK1341791T3 (en) 2005-09-19
CA2431151A1 (en) 2002-06-13
US20040092545A1 (en) 2004-05-13
JP2004515500A (en) 2004-05-27
WO2002046189A2 (en) 2002-06-13
EE200300274A (en) 2003-10-15
IL155884A0 (en) 2003-12-23
US7612083B2 (en) 2009-11-03
HUP0700062A2 (en) 2007-05-02
NO20032595L (en) 2003-06-06
JP2004532810A (en) 2004-10-28
WO2002046188A2 (en) 2002-06-13
EP1341791B1 (en) 2005-05-25
ZA200305275B (en) 2004-10-08
NZ526089A (en) 2004-11-26
AU2002239517B2 (en) 2006-11-02
ES2281456T3 (en) 2007-10-01
DK1341790T3 (en) 2007-06-04
NZ526105A (en) 2004-11-26
DE60126645D1 (en) 2007-03-29
AR035666A1 (en) 2004-06-23
WO2002046192A3 (en) 2003-02-13
EP1339715A2 (en) 2003-09-03
CA2436984A1 (en) 2002-06-13
HRP20030462A2 (en) 2004-04-30
JP2004529078A (en) 2004-09-24

Similar Documents

Publication Publication Date Title
CA2436846C (en) Thioether substituted imidazoquinolines
US6664264B2 (en) Thioether substituted imidazoquinolines
US6667312B2 (en) Thioether substituted imidazoquinolines
AU2002239530A1 (en) Thioether substituted imidazoquinolines
US6660747B2 (en) Amido ether substituted imidazoquinolines
US20020107262A1 (en) Substituted imidazopyridines
AU2002232497A1 (en) Urea substituted imidazoquinoline ethers
EP1541572A1 (en) Thioether substituted imidazoquinolines
AU2002315009B2 (en) Thioether substituted imidazoquinolines

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20141208